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Abstract 
Background: The rare nature of male breast cancer (MBC) has led to its 
management being guided by the extensive research conducted in the field of 
female breast cancer (FBC). The aim of this study was to evaluate MBC at both 
protein and molecular level to improve understanding of its pathology. 
  
Methodology: Immunohistochemistry analysis was performed in MBC (n=428) 
TMAs for 18 biomarkers (ERα, ERβ1, ERβ2, ERβ5, Total PR, AR, CK5/6, 
CK14, CK18, CK19, p53, Bcl-2, Her2, E-cadherin, Ki67, Survivin, Prolactin and 
FOXA1). The manual scoring of ERα and Ki67 was correlated with a fully 
automated immunohistochemistry image analysis system (ImmunoRatio™). 
Finally gene expression profiling (GEP) was undertaken in matched MBC 
(n=15) and FBC (n=10) samples. 
 
Results: There was poor 5 year overall survival (OS) in CK18 and CK19 
negative patients (p= 0.05; p= 0.003), as well as poor 10 year OS in CK19 
negative patients (p= 0.002). Age (p= 0.001) and nodal status (p= 0.04) was 
found to be independent predictors of OS at 5 years.  
  
There was significant correlations between manual and ImmunoRatio™ ERα 
(ρ= 0.872; p= 0.000) and Ki67 (r= 0.675; p= 0.000) scores. However due to a 
low measure of agreement it was not possible to validate Ki67 scoring using 
ImmunoRatio™.  
 
The functional enrichment analysis of GEP data using less stringent criteria (p < 
0.05) identified 735 differentially expressed genes. The data analysis showed 
up-regulation of genes involved in ECM synthesis, degradation and re-
modelling in MBC. The end product of one of the up-regulated genes 
(Fibronectin (FN1)) was validated in the MBC cohort with high fibronectin 
expression (60%) being positively associated with nodal status and showed a 
trend towards poor 5 year OS (p= 0.06).  
 
Conclusion: In MBC, epithelial cytokeratins, especially CK19 was found to be 
of prognostic significance. The extracellular matrix remodelling associated 
genes were found to be up-regulated in MBC. Fibronectin, end product of one of 
the up-regulated gene was found to have prognostic significance in MBC.   
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1 Male Breast Cancer Overview
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1.1 INTRODUCTION  
1.1.1 Male Breast Cancer  
Male breast cancer (MBC) is uncommon and accounts for approximately 1% of 
the breast cancers diagnosed (Callari et al., 2011, Shaaban et al., 2012, White 
et al., 2011). MBC accounts for only 0.1% of male cancer deaths (Jemal et al., 
2008) but its annual incidence continues to increase by 1.1% (Giordano et al., 
2002a). However, the improvements in overall survival seen over the years in 
female breast cancer (FBC) have not been observed in MBC primarily due to 
the poor understanding of the pathology due to the lack of large prospective 
trials. Hence, the management of MBC is currently based on the information 
extrapolated from the immense research undertaken in the field of FBC.  
1.1.2 Epidemiology  
The worldwide distribution of MBC incidence resembles that of FBC with the 
highest incidence seen in North America and Europe and  lower rates in Asia 
(Ravandi-Kashani and Hayes, 1998). The incidence of MBC is increasing but at 
a slower rate than FBC (Ewertz, 1996, Shavers et al., 2003). The National 
Cancer Institute data from the United States of America (USA) shows that the 
incidence of MBC has risen to 1.08 from 0.86 per 100,000 men (Giordano et al., 
2004). The incidence in the United Kingdom (UK) is similar to that in the USA 
with just under 1% (n=334) diagnosed with MBC in 2012 (CRUK, 2012). The 
incidence of MBC is considerably higher (15%) in sub-Saharan Africa, which 
has been mainly attributed to the hyper-oestrogenism from liver damage due to 
the prevalence of endemic infectious diseases like Schistosomiasis (Andersen 
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and Gram, 1982, Carlsson et al., 1981). The prevalence of MBC increases with 
age but unlike FBC it has a unimodal distribution with the peak seen at late 
sixties and early seventies (Anderson et al., 2004, Giordano et al., 2004). 
Hence the average age at diagnosis for MBC is at least 10 years older than that 
for FBC (Devesa et al., 1995, Hill et al., 2005). Moreover, there have not been 
any screening programmes for MBC which can distort the pattern of age at 
diagnosis as seen in FBC.  
The racial predilection of MBC is unique and different compared to that of FBC. 
There is a relative increase in the incidence of MBC compared to FBC amongst 
people of African-American origin (Crew et al., 2007, Nahleh et al., 2007). This 
is in sharp contrast to the consistently higher incidence of FBC seen amongst 
post-menopausal Caucasian women compared to African-American women 
(Anderson et al., 2004). A higher risk for developing MBC has been shown 
amongst Jews, with younger age at presentation for the Sephardic Jews and an 
increased life time risk for the Ashkenazi Jews (Brenner et al., 2002, Steinitz et 
al., 1981). 
1.1.3 Aetiology and Risk Factors 
The unimodal age-frequency distribution of breast cancer incidence suggests a 
hormone independent epithelial carcinogenesis in MBC (Pike et al., 1983). 
However, hormonal imbalance due to liver disease, Klinefelter’s syndrome and 
obesity have been implicated in the causation of MBC. It has been established 
through previous published studies that, hormonal imbalances through change 
in the oestrogen-testosterone ratio can predispose to MBC (Ballerini et al., 
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1990, Casagrande et al., 1988). An elevated oestradiol level was observed in 
MBC patients compared to controls in the published literature (Sasco et al., 
1993, Brinton et al., 2015). Moreover, the recent evidence from the Male Breast 
Cancer Pooling Project reveals obesity increases the risk of MBC (Brinton et al., 
2014, Humphries et al., 2015). The elevated circulating level of oestrogen in 
obese men is thought to be due to the aromatization of androgens with 
conversion of testosterone to oestradiol and androstenedione to oestrone in 
peripheral adipose tissue (Hsing et al., 1998). Hormonal imbalance can be 
worsened due to a decrease in the sex hormone binding globulin, leading to a 
greater amount of bio-available oestrogen in obese men (Casagrande et al., 
1988).  
The hormonal imbalance seen in patients with gynaecomastia and Klinefelter’s 
syndrome has drawn the attention of researchers to explore whether there is a 
causative relationship to MBC. The most recent evidence from the Male Breast 
Cancer Pooling Project has shown increased risk for the development of MBC 
associated with both gynaecomastia and Klinefelter’s syndrome (Brinton et al., 
2014). Elevated levels of oestrogen due to chronic liver disease (cirrhosis), 
exogenous administration of oestrogen (transsexuals) or iatrogenic oestrogen 
therapy (for prostate cancer) have been implicated as risk factors for MBC 
(Contractor et al., 2008). Androgen deficiency due to underlying testicular 
conditions such as mumps orchitis, undescended testes and testicular injury 
has also been linked to MBC (Mabuchi et al., 1985, Thomas et al., 1992).  
However the strongest proven relationship is between MBC and Klinefelter’s 
syndrome due to testosterone deficiency (Hultborn et al., 1997).  
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Other risk factors for MBC are environmental/occupational factors such as 
exposure to ionizing radiation and chronic heat (Brinton et al., 2008, Ottini et al., 
2009). It has been proposed that, the environmental and occupational factors 
either directly or indirectly lead to testicular damage resulting in the causation of 
MBC (Rosenbaum et al., 1994, Stenlund and Floderus, 1997). The individual 
studies conducted to evaluate the association between electromagnetic fields 
(EMF) and MBC had inherent biases with type II error, selection bias (miss-
classification of the EMF exposure) and recall bias (Weiss et al., 2005). 
However, a subsequent meta-analysis showed that the exposure of EMF 
increases the risk of breast cancer by 1.37 times (CI, 1.11-1.71) in men (Erren, 
2001). Unlike FBC, there is little reliable evidence to conclude any association 
between dietary intake and MBC (Weiss et al., 2005). 
Category  Known risk factors Inconclusive evidence 
Genetic factors BRCA2 
Family history –Ashkenazi Jews 
Klinefelter’s syndrome 
AR gene 
CHECK2 
PTEN 
Hormonal 
imbalance 
Obesity 
Gynaecomastia 
Cirrhosis 
Testicular disorders 
Cryptorchidism 
Mumps orchitis 
Orchidectomy 
Prostate cancer 
Environmental  Ionizing radiation EMFs 
Occupational exposure 
High temperature 
Diet and alcohol 
Iatrogenic  Exogenous oestrogen 
Radiotherapy 
Fluoroscopy 
Prostate cancer treatment 
 
Table 1: Risk factors for Male Breast Cancer  
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1.1.4 Genetics 
A positive family history has been associated with an increased risk for MBC but 
unlike FBC the risk cannot be quantified primarily due to the rarity of the 
disease resulting in a lack of information to calculate risk estimates. However, it 
has been estimated that a positive family history of male or female breast 
cancer among first degree relatives increases MBC risk by 2 or 3 folds (Weiss 
et al., 2005). Similarly, the diagnosis of MBC in a first degree relative is a 
substantial risk factor for development of future breast cancer in women. It is 
well established that as with other solid tumours, the development of MBC is a 
multi-step process and genomic DNA alteration playing an important role 
(Tommasi et al., 2010). The DNA alteration by amplification or deletions leads 
to changes in the gene expression, which alter key cellular processes 
downstream for the development of breast cancer.  
In comparison to FBC, where there is a strong inherited susceptibility (30-86%) 
for rare high penetrance mutations (Ford et al., 1998, Tischkowitz et al., 2002), 
such mutations are observed only in 4 to 40% of MBC (Friedman et al., 1997, 
Haraldsson et al., 1998, Thorlacius et al., 1997). BRCA 2 gene mutation is 
frequent and accounts for 4 to 40% of patients with MBC (Callari et al., 2011). In 
comparison to FBC, BRCA2 mutations confer 6 to 9% life time relative risk of 
developing breast cancer in men in the Western world (Evans et al., 2010). In 
the Cambridge series, 8% of the patients with MBC were found to have BRCA2 
mutations in comparison to 40% in the Icelandic series, which is the largest 
incidence reported so far in the literature (Basham et al., 2002, Thorlacius et al., 
1996). The high incidence seen in the Icelandic series has been attributed to 
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the founder mutation of 999del5 in the BRCA2 gene (Thorlacius et al., 1996). 
The wide variation seen amongst various studies may suggest broad genetic 
variation across the population. However caution needs to be exercised while 
interpreting these results due to the small sample size. There is evidence to 
suggest 50-92% of familial breast cancer arises from BRCAX families, however 
the underlying mechanism remains uncertain (Besic et al., 2008, Ahn et al., 
2004) 
Klinefelter’s syndrome is a rare chromosomal abnormality of 47 XXY karyotype 
and occurs in 1:1000 men (Evans and Crichlow, 1987, Lynch et al., 1999). In 
Klinefelter’s syndrome, proliferation of the mammary ductal epithelium due to 
alteration in the androgen-oestrogen ratio has been implicated in the causation 
of cancer (Newman, 1997, Thomas, 1993). The reported incidence of 
Klinefelter’s syndrome in MBC ranges from 3 to 4% (Lynch et al., 1999) with a 
20 fold increased risk of developing breast cancer in comparison to males 
without this condition (Newman, 1997, Thomas, 1993).  
Even though there has not been any causal relationship established, the 
commonest genetic mutations that have been associated with MBC are the 
polymorphism in the CYP17 gene involved in steroid synthesis and mutation of 
the CHEK2 (Falchetti et al., 2008) and PTEN tumour suppressor genes 
(Cowden syndrome) (Yang et al., 2010). CYP17 gene encodes for the 
P450c17α enzyme involved in the synthesis of oestrogen and androgens. The 
increased transcriptional activity due to the T-to-C polymorphism at the 
5’untranslated region has been hypothesised to enhance the steroid hormone 
production and lead to alteration in the oestrogen-androgen ratio leading to an 
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increased risk of developing cancer (Carey et al., 1994). The level of evidence 
to support this association in MBC is weak and clearly more evidence is needed 
to elucidate this causative relationship (Dunning et al., 1998, Gudmundsdottir et 
al., 2003).  
Cowden syndrome is an autosomal dominant disease characterized by multiple 
hamartomas and associated with germ line mutations in the PTEN tumour 
suppressor gene (Fackenthal et al., 2001). In women, Cowden syndrome has 
been implicated with an increased risk for breast and thyroid cancers as well as 
many non-cancerous lesions (Weiss et al., 2005). Similarly, it is proposed that 
the PTEN mutation contributes to MBC and an association has been drawn with 
earlier onset of cancer (Fackenthal et al., 2001).  
The CHEK2 gene encodes for the cell cycle check point kinase involved in DNA 
repair process involving BRCA1 and P53 (Meijers-Heijboer et al., 2002, Weiss 
et al., 2005).  Mutation of the CHEK2*1100delC has been associated with a 10 
fold increased risk of developing MBC in families who do not harbour the 
BRCA1/2 mutations (Meijers-Heijboer et al., 2002). The Breast Cancer 
Consortium study has proposed that as much as 9% of MBC can be attributed 
to CHEK2 mutation (Meijers-Heijboer et al., 2002). However more recent 
studies failed to reproduce this finding with a far lower incidence of CHEK2 
mutation noted (0 to 1.8%) in MBC patients (Neuhausen et al., 2004, Ohayon et 
al., 2004, Syrjakoski et al., 2004). Hence there is a school of thought that, the 
higher incidence noted in the Dutch studies (Meijers-Heijboer et al., 2002, 
Wasielewski et al., 2009) may be inherent to the population studied and may 
not be widely representative.  
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A germline mutation of the AR gene was explored in detail by various 
researchers, with some implicating long polyglutamine repeats of the AR 
receptor in MBC (Young et al., 2000) but not others (Friedman et al., 1997, 
Syrjakoski et al., 2003). Imbalance of the androgen and oestrogen ratio due to 
mutation of AR gene and binding of the AR promoter to oestrogen response 
elements (Haraldsson et al., 1998, Young et al., 2000) has also been implicated 
in the development of MBC. 
There is more evidence emerging from high throughput studies on MBC 
genomic landscape. In a recent study, recurrent mutations of PIK3CA, GATA3, 
TP53 and MAP3K1 genes were observed in MBC (Piscuoglio et al., 2016). 
However in comparison to ER+/Her2- FBC, PIK3CA and TP53 mutations were 
less frequent in MBC with more frequent mutations of genes associated with 
DNA repair (PALB2 and FANCM) (Piscuoglio et al., 2016).  
1.1.5 Clinical presentation 
Male breast cancer presents typically as a hard eccentric non-tender breast 
mass in almost 75 to 95% of the patients (Gennari et al., 2004). The central 
sub-areolar region is the most common site for cancer in men (Goss et al., 
1999, Stierer et al., 1995) compared to the upper outer quadrant in women. The 
Surveillance, Epidemiology and End Result (SEER) data confirms that there is 
no evidence of lateralisation amongst MBC (Weiss et al., 1996)]. The mean size 
of the MBC at diagnosis is larger than that of FBC (Giordano et al., 2004). 
Involvement of the nipple areolar complex is quite common (40 to 50%) as a 
reflection of the small amount of breast tissue present leading to skin retraction, 
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fixation, nipple discharge and areolar changes (Contractor et al., 2008). The 
presence of skin ulceration is a more common sign at presentation amongst 
MBC than FBC (Wagner et al., 1995). The central location of the tumour along 
with small amount of breast tissue results in early ulceration in MBC. Unlike 
FBC, axillary nodal involvement has been reported in as many as 40 to 55% of 
the patients reflecting the overall increased stage at diagnosis (Lefor and 
Numann, 1988). In a population based study it was shown that, axillary nodal 
metastases were found in 37.7% with MBC and 29.2% with FBC (Gentilini et al., 
2007). When interpreting these findings, it is important to consider that the lower 
axillary nodal burden amongst women may have been influenced by the earlier 
detection of breast cancer through breast screening programmes.  
1.1.6 Pathological features  
Invasive ductal carcinoma is the most common histological type among MBC 
(64-93%) followed by papillary carcinoma (2.6 to 5%) (Cutuli et al., 1995, 
Donegan et al., 1998, Shaaban et al., 2012). Invasive lobular carcinoma is rare 
amongst males (Giordano et al., 2004, Tischkowitz et al., 2002). The rest of the 
histological types including medullary, tubular and mucinous cancer constitute 
less than 15% of MBC (Contractor et al., 2008). Ductal carcinoma in situ (DCIS) 
constitutes around 5% of MBC and in almost 75% of the cases it is of the 
papillary subtype which is a markedly higher proportion than that observed in 
women (Hittmair et al., 1998). Studies to date have not conclusively established 
the prognostic significance of grade in MBC (Giordano et al., 2002a, Ravandi-
Kashani and Hayes, 1998). 
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1.1.7 Molecular classification 
Genome-wide profiling techniques have been used to study FBC extensively in 
the last decade. Perou et al (2000) described distinct intrinsic subtypes (Luminal 
A, luminal B, Her2 enriched, Basal or triple negative) using gene expression 
profiling. Since then it has been established that, the Luminal A subtype has got 
the best outcome and worst outcome for Her2 and Basal subtypes (Sorlie et al., 
2003). Since then the prognostic significance of these subtypes has been 
externally validated and refined (Hu et al., 2006). It has been also possible to 
use biomarkers as surrogate to replicate the prognostic significance of intrinsic 
subtypes using immunohistochemistry (Carey et al., 2006).  
The genomic aberrations has also been used to classify FBC in to molecular 
subgroups. Fridlyand et al (2006) classified FBC in to 3 subgroups of clinical 
significance, simple, mixed amplifier and complex. These subgroups has been 
externally validated by Chin et al (2006). The high resolution array comparative 
genomic hybridisation (aCGH) method was used by Jonsson et al (2010) more 
recently to classify FBC in to six different subgroups. These were Luminal 
simple, Luminal complex, Basal complex, Amplifier, Mixed and 17q12 
subgroups. The Amplifier and Mixed subgroups contained all FBC intrinsic 
subtypes, whereas Luminal complex subgroup consisted of Luminal B and 
majority of BRCA2. The Luminal A subtype was present in Luminal simple and 
complex groups. The Luminal simple subgroup was found to have the best 
prognosis in the group. The Basal complex group consisted of majority of 
BRCA1 patients. The 17q12 subgroup consists of Her2 enriched subtype and 
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had the worst prognosis. The findings from these studies further illustrate and 
consolidate the heterogeneous nature of FBC.  
The rare nature of MBC resulted in a paucity of studies conducted using 
genome-wide profiling methods. Earlier studies using comparative genomic 
hybridisation (CGH) showed similarities amongst male and female breast 
cancer in chromosomal gains and losses (Rudlowski et al., 2006). However it 
was only recently more advanced aCGH methods were used in an attempt to 
classify MBC in to molecular subtypes (Johansson et al., 2011, Tommasi et al., 
2010). Based on the results of the aCGH, Johansson et al (2011) managed to 
classify MBC in to, male simple and complex groups. There was some similarity 
between the male complex and female complex subgroup. Whereas, male 
simple group was less aggressive and was associated with better outcome.  
There was attempt to further understand the similarities and differences 
between male and female breast cancer by classifying MBC using gene 
expression profiling (Johansson et al., 2012). They identified 2 unique 
subgroups, luminal M1 and luminal M2 which correlated well with male complex 
and simple subgroups respectively. However they were different from the well-
established FBC intrinsic subtypes. The luminal M1 subgroup was more 
frequent and aggressive phenotype compared to luminal M2, which was 
associated with better prognosis.  
1.1.8 Clinical management  
The diagnostic methods used for evaluating men presenting with a breast 
symptoms are similar to those used in women. Patients who present with breast 
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lumps are evaluated using triple assessment. A careful history and clinical 
examination are critical in the evaluation of men presenting with breast 
symptoms. The paucity of breast tissue makes the radiological evaluation using 
mammography more challenging and hence traditionally assessed initially using 
an ultrasound. However, mammography has been shown to have good 
sensitivity (92%) and specificity (90%) for detecting MBC in some series (Evans 
et al., 2001). Conventionally tissue samples are obtained for histological 
diagnosis either using fine needle aspiration cytology (FNAC) or preferentially 
using core biopsy (CB).  
The treatment of MBC is largely based on the evidence and experience gained 
from managing FBC. Similar to FBC, there has been a shift in the surgical 
management of MBC from radical mastectomy to simple mastectomy. This was 
supported by various studies which failed to show any overall or disease free 
survival advantage for MBC patients treated with radical procedures (El-Tamer 
et al., 2004, Margaria et al., 2000). The relatively small amount of breast tissue 
in men (1/100 of that of women) have led to fewer breast conservation surgeries 
to treat MBC (Goss et al., 1999). The indications for adjuvant radiotherapy in 
MBC remain controversial due to inconclusive and inconsistent results 
published in the literature. Some suggest that adjuvant radiotherapy should be 
given to all the MBC patients due to the lack of sufficient breast tissue 
preventing adequate surgical clearance (Vetto et al., 1999). However, the low 
recurrence rates achieved after surgery alone without radiotherapy have 
challenged this approach (Chakravarthy and Kim, 2002, Chung et al., 1990).  
Similar to the role of radiotherapy, radiotherapy field is also controversial as 
there is limited data to suggest which MBC patients should receive radiotherapy 
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to chest wall or axilla or supraclavicular fossa. However, there is general 
consensus to advice adjuvant radiotherapy to those patients with a high risk of 
local recurrence as identified in FBC trials such as those with large tumours, 
four or more involved axillary lymph nodes, extra-capsular nodal extension and 
those with close surgical margins (Contractor et al., 2008, Volm, 2003).  
The management of axillary disease has evolved and changed over the past 
few decades. Prior to the introduction of sentinel lymph node biopsy (SLNB) in 
the late 90’s, the standard management of axillary disease in men and women 
was axillary node clearance (ANC). However, since then the wide acceptance 
of SLNB as an accurate staging and perhaps therapeutic procedure in FBC 
made it the standard procedure in MBC patients without any radiologically or 
histologically proven axillary lymph node involvement (Cimmino et al., 2004, 
Schuchardt et al., 1996). Currently, SLNB is considered as the standard for 
managing patients with early primary MBC (Albo et al., 2003, Cimmino et al., 
2004). 
Adjuvant hormonal therapy has also evolved over the years from surgical anti-
hormonal ablative procedures (Orchidectomy, Adrenalectomy and 
Hypophysectomy) through to hormonal manipulation using oral/injectable 
medications. Amongst the various agents tested, mild to moderate success has 
been reported for diethylstilboestrol (Ribeiro, 1976, Lopez et al., 1985), 
cyproterone acetate (Pannuti et al., 1982), androgens (Kantarjian et al., 1983, 
Ribeiro, 1976), luteinizing hormone releasing agonist alone or in combination 
with anti-androgens (Doberauer et al., 1988, Vorobiof and Falkson, 1987). 
There are not any prospective or randomized studies undertaken to establish 
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the role of adjuvant hormonal therapy in MBC. The current clinical practice of 
administering tamoxifen to MBC patients has emerged from its well established 
role in oestrogen receptor (ER) positive FBC and the established high ER 
positivity (75-80%) in MBC. The proven benefit of aromatase inhibitors (AI) in 
post-menopausal women with breast cancer has led to studies exploring its role 
in MBC. The first generation of AI such as aminoglutethimide were shown to be 
effective in MBC patients who had undergone orchidectomy (Harris et al., 1986, 
Patterson et al., 1980). In orchidectomised patients, the lack of additional 
oestrogen production from the testes leads to a more effective action of the AIs 
to prevent the conversion of androgen to oestrogen. The third generation AIs 
(Anastrazole, Exemestane and Letrozole) are more specific and are used in the 
management of post-menopausal women with FBC. However there are some 
theoretical reservations about aromatase activity in men and there is a scarcity 
of evidence within the literature especially randomized controlled trails 
regarding the role of third generation AIs in the adjuvant settings for MBC 
(Giordano et al., 2002b, Italiano et al., 2004). 
 Similarly, even though there is no conclusive evidence regarding the role of 
adjuvant chemotherapy in MBC patients, its beneficial role in high risk patients 
(locally advanced and/or node positive) has been established through large 
central reviews (Contractor et al., 2008) and prospective studies (El-Tamer et 
al., 2004, Patel et al., 1989). Various regimens have been tried in MBC, with 
historically the vast majority of the studies using CMF (Cyclophosphamide, 
Methotrexate and 5-fluorouracil) (Bagley et al., 1987, Patel et al., 1989), and 
more recently anthracycline and taxane based regimens (Giordano et al., 2005, 
Patel et al., 1989).  
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1.1.9 Prognosis and prognostic markers 
In contrast to FBC, there has been little improvement in the survival of patients 
diagnosed with MBC (Johansson et al., 2012). The incidence of local 
recurrence is higher amongst MBC patients possibly due to the smaller volume 
of the breast tissue enhancing lymphatic infiltration and invasion of the 
underlying muscles (Wagner et al., 1995, Winchester, 1996). The reported 5 
year survival rates for MBC ranges from 40 to 65% (Cutuli et al., 1995, Wagner 
et al., 1995). It has been shown that the worse prognosis seen amongst MBC 
patients in comparison to FBC disappear once it has been corrected for the age 
and stage at diagnosis (Evans et al., 2001, Adami et al., 1985, Willsher et al., 
1997b). However worse survival is observed in male patients with stage III and 
IV disease compared to their female counterpart, whereas similar 5 year 
survival rates were observed for stage 0, I and II disease (Scott-Conner et al., 
1999). The relative prognosis of MBC therefore remains somewhat uncertain.  
Tumour stage (Giordano et al., 2004, La Vecchia et al., 1992, Fonseca et al., 
2006)  and axillary nodal status on its own (Guinee et al., 1993, Pich et al., 
1999) has been shown over the years by various researchers to be the most 
consistent and reliable independent prognostic factor influencing overall survival 
(OS) in MBC patients. The role of tumour grade as a prognostic factor in MBC is 
controversial due to the lack of consistency in the published results (Salvadori 
et al., 1994). Smaller studies have shown a relative higher grade in MBC 
compared to FBC (Muir et al., 2003), whereas the larger SEER database 
analysis didn’t reveal any significant difference (Giordano et al., 2004, Giordano 
et al., 2002a). Tumour size was also suggested to be an independent predictor 
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of overall survival by various researchers (Anderson et al., 2004, Giordano et 
al., 2004). 
The prognostic role of various biomarkers has been explored in MBC without 
any biomarker identified conclusively as a prognosticator due to the 
inconsistencies in the published literature. Even though ER and PR are highly 
expressed in MBC, the prognostic role of both these biomarkers was 
insignificant after accounting for other clinical and pathological prognostic 
factors (Giordano et al., 2004, Goss et al., 1999, Truong et al., 2005, Wang-
Rodriguez et al., 2002). Individual studies have shown better overall survival 
amongst ER positive MBC (Donegan et al., 1998, Wang-Rodriguez et al., 
2002), whereas ER positivity was not found to be a significant predictor of 
overall survival on multivariate analysis (Goss et al., 1999). The roles of AR 
(Pich et al., 1999, Kwiatkowska et al., 2003), c-erbB2 (Joshi et al., 1996, 
Willsher et al., 1997a) and p53 (Wang-Rodriguez et al., 2002, Willsher et al., 
1997a) have been similarly explored without reaching any consensus on their 
prognostic significance in MBC. 
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2 Protein Biomarker Analysis in 
Male Breast Cancer Cohort  
21 
 
2.1 INTRODUCTION 
Male breast cancer arises in a different hormonal milieu than that of FBC but it 
remains uncertain whether they behave similarly or not. Researchers over the 
years have tried to evaluate the level of expression and the interactions of 
various biomarkers in MBC that have been previously evaluated in FBC. 
However, the low incidence and prevalence of MBC led to small sample size 
and hence a lack of power of the observed findings.  
High expression of steroid receptors, especially oestrogen (ER) and 
progesterone receptor (PR) has been observed in MBC compared to FBC 
(Contractor et al., 2008).  It has been hypothesised that the up-regulation of the 
steroid receptor in an oestrogen depleted environment as seen in post-
menopausal women may be responsible for this (Muir et al., 2003). However 
unlike the post-menopausal FBC, higher grade and proliferation rates were 
observed in ER positive MBC (Muir et al., 2003, Munoz de Toro et al., 1998). It 
was also shown that, grade 3 MBC were more frequently ER and PR positive 
and negative for p53 and ERBB2 compared to grade 3 FBC (Muir et al., 2003). 
This indirectly indicates that up-regulation of ER leading to activation of 
downstream targets such as p53 and/or ERBB2 may not persist in MBC. 
Moreover the oestrogen modulated proteins (Cathepsin D, protein S2 (pS2) and 
heat shock protein 27 (hsp27)) were also differentially expressed in male and 
female breast cancer (Muir et al., 2003). 
 It was previously established that proteins (Alpha-2-Zn-glycoprotein and 
Apolipoprotein D) under androgen control are differentially expressed in MBC 
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compared to FBC, even though their prognostic roles were uncertain (Muir et 
al., 2003). The functional studies performed have shown a greater role for 
androgen receptor (AR) in MBC compared to ER (Weber-Chappuis et al., 
1996a). However the expression levels of AR in MBC have been variably 
reported within the literature, ranging from minimal up to 95% (Contractor et al., 
2008). Hence it shouldn’t be unreasonable to suggest that the ER function in 
MBC is different compared to FBC. 
In an oestrogen depleted environment, up-regulation of ER can lead to an 
increased response to oestrogen targets such as the Bcl-2 (Nahleh and Girnius, 
2006). Bcl-2 is an inhibitor of apoptosis and when up-regulated can lead to 
malignant transformation through genomic modification and downstream target 
activation (Muir et al., 2003). Bcl-2 was shown to be over expressed in MBC 
compared to FBC (Rayson et al., 1998, Weber-Chappuis et al., 1996a, Muir et 
al., 2003). It was proposed that, the high expression of Bcl-2 in MBC through 
stimulation of  growth factors (Leek et al., 1994) can lead to inhibition of 
apoptotic cell death and therefore can influence carcinogenesis (Rayson et al., 
1998). However, unlike in FBC, the prognostic role of Bcl-2 in MBC remains 
uncertain. 
Cytokeratins (CK) were shown to play an important role in the carcinogenesis of 
FBC (van de Rijn et al., 2002, Korsching et al., 2002, Malzahn et al., 1998). 
Cytokeratin expression profiles vary between different breast epithelial 
compartments. Some cytokeratins (CK5/6, CK14 and CK17) are principally 
expressed in the basal/myoepithelial cell phenotype, whereas others (CK8, 18 
and 19) represent luminal differentiation (Ciocca et al., 2006). Female breast 
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cancer was classified based on molecular profiling in to different subgroups.  
The CK, ER, PR and Her2 (Human Epidermal Growth Factor receptor -2) 
immunohistochemistry (IHC) expression was used as a surrogate for the earlier 
gene expression profiling described by Perou et al (2015).  For example basal 
like subtype would be ER-, PR-, HER2- and CK5/6+; this surrogate for 
molecular subtype permits the use of IHC for the evaluation of breast cancers 
(Carey et al., 2006, Nielsen et al., 2004). The incidence of CK5/6 and CK14 
positive tumours in FBC is approximately 10-15%,  with higher incidences noted 
in African-Americans (van de Rijn et al., 2002) and similar observations are 
noted in MBC (Ciocca et al., 2006). However, unlike in FBC, the clinical 
significance or prognostic role of any of the cytokeratins in MBC has not been 
explored.  
Human Epidermal Growth Factor receptor - 2 (Her2) over expression patterns 
and frequency in MBC is controversial with reported values ranging from 0-95% 
(Rayson et al., 1998, Ravandi-Kashani and Hayes, 1998). Unlike in FBC, there 
is still dispute about its prognostic significance in MBC. Over expression of Her2 
has been associated with poor prognosis by some (Bloom et al., 2001, Reed et 
al., 2000), whereas others have failed to identify any prognostic significance in 
MBC (Tischkowitz et al., 2002, Muir et al., 2003). 
The tumour suppressor gene p53 regulates the progression of the cell cycle in 
the presence of DNA damage. Over expression of p53 in FBC has been 
associated with a poor prognosis (Shpitz et al., 2000, Willsher et al., 1997b, 
Plesan et al., 2010). Conversely, p53 was over expressed only in < 10% of 
MBC with some researchers showing poor prognosis (Anelli et al., 1995, Joshi 
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et al., 1996, Pich et al., 1996, Weber-Chappuis et al., 1996a, Willsher et al., 
1997b), whereas others showed no correlation (Clark et al., 2000). It has been 
proposed that, a different p53 mutational profile in males compared to females 
may result in lack of over expression of p53 leading to the inability of the 
immunohistochemistry methods to detect the protein (Muir et al., 2003). 
Ki-67 is a known proliferation marker expressed in all cells that are not in the 
resting phase (G0) of the cell cycle and has been associated with poor survival 
in FBC (Pinder et al., 1995). Similar to FBC, correlation has been established 
between Ki67 and poor progression free survival in MBC (Rayson et al., 1998). 
It is estimated that, around 20 to 40% of the MBC show high expression of Ki67 
(Wang-Rodriguez et al., 2002). However, majority of the studies in the past 
used varying cut-off for determining Ki67 expression. In MBC, some correlation 
was drawn between positive Ki67 expression and lymph nodal metastasis 
(Anderson et al., 2002).  However, there is still lack of good quality evidence 
within the literature to substantiate the role of Ki67 as a prognostic biomarker in 
MBC.  
Survivin is a member of the inhibitor of apoptosis family (IAP) and it regulates 
cell division, inhibits apoptosis and enhances angiogenesis (Velculescu et al., 
1999, Tran et al., 1999). Due to its anti-apoptotic property, high survivin 
expression has been generally correlated with poor prognosis (Ryan et al., 
2006). In FBC, survivin expression has been correlated with known poor 
prognostic markers by some (Brennan et al., 2008, Al-Joudi et al., 2007, Hinnis 
et al., 2007), whereas others have found no such correlation (Kennedy et al., 
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2003). However, the only study conducted in a small cohort of MBC patients 
failed to establish any prognostic significance for survivin (Younis et al., 2009). 
Epidemiological studies have shown high serum prolactin (PRL) to be 
associated with an increased risk of developing breast cancer in pre-
menopausal (40%) and post-menopausal women (30%) (Tworoger and 
Hankinson, 2008). Unlike in the female breast, PRL does not influence the 
growth of normal male breast tissue. There is lack of evidence about the role of 
PRL or its receptor (PRLR) in MBC and to date there is only a single study 
within the literature which evaluated the biomarker expression of PRLR in MBC  
and in patients with gynaecomastia (Ferreira et al., 2008). They observed 
higher expression of PRLR in MBC compared to gynaecomastia tissue but 
there was no correlation with ER, PR, AR, grade or stage of the disease. 
The evidence available within the literature suggests potential differences in 
biomarker expression between male and female breast cancer. However due to 
the scarcity of studies in MBC compared to FBC, there is lack of information 
about the clinical significance and prognostic role of biomarkers in MBC. Hence, 
it would be valuable to evaluate the expression, interactions and prognostic 
roles of various biomarkers (selected based on their role in FBC) in a large 
cohort of MBC. 
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2.2 HYPOTHESIS 
We hypothesised that, there will be fundamental differences at protein level 
between male and female breast cancer that could explain MBC development 
and progression. In order to evaluate this, various known biomarkers with 
established role in FBC (ERα, ERβ1, ERβ2, ERβ5, Total PR, AR, CK5/6, CK14, 
CK18, CK19, p53, Bcl-2, Her2, E-cadherin, Ki67, Survivin, Prolactin and 
FOXA1) were studied immunohistochemically in MBC tissue microarrays.    
2.2.1 Aims 
1) Evaluate the expression levels of various biomarkers and correlate their 
expression with known clinical or pathological prognostic variables in a large 
cohort of MBC 
2) Identify any prognostic or predictive role for selected biomarkers in MBC  
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2.3 METHODOLOGY  
Immunohistochemistry analysis was performed in tissue micro arrays (TMAs) 
constructed from formalin fixed paraffin embedded (FFPE) tissue blocks from 
428 male breast cancers. These blocks were collected through collaboration by 
Prof. Speirs with various pathologists across the United Kingdom (n=243), 
Canada (n= 53), Italy (n = 50), Hungary (n=42), Poland (n=31), and Nigeria 
(n=9). MBC tissues were incorporated in to 8 TMA blocks to standardise and 
maximise the information gathered using IHC analysis. The ethical approval for 
the study was obtained from the Leeds (West) Research Ethics Committee 
(06/Q1205/156) (Appendix 1, Page no. 177). 
The clinical and pathological prognostic parameters were provided 
anonymously by the institution providing the MBC tissue blocks (where 
available) and held on a secure password-protected electronic database at the 
University of Leeds.  The electronic data base (Patient Pathway Manager) held 
at Leeds Teaching Hospitals NHS Trust (LTHT) was searched retrospectively 
for tissue blocks originating locally. The variables collected included, age and 
date of diagnosis, type of surgery, adjuvant therapies, development of loco-
regional recurrence, distant metastasis and survival data. Histological features 
including, type of cancer, tumour size, grade, nodal status, lympho-vascular 
invasion (LVI), presence of DCIS, hormonal receptor status and TNM staging 
information were collected from the pathological data base (CoPath) held at 
LTHT. The data was anonymised through assigning a unique MBC identification 
number to each tissue block which was stored in the central database.  
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2.3.1 Microtomy 
The FFPE tissue was sectioned using the manual rotary microtome (LeicaTM 
rm2235). Disposable blades were used for sectioning with a clearance angle of 
3º to 4º with the angle of the slope pre-set at 40º. The TMA block was fixed onto 
the microtome and trimmed using an old blade to remove any excess wax until 
a suitable tissue section was exposed. Subsequently the TMA block was placed 
on melting ice for 15 to 30 minutes to facilitate sectioning by cooling of the wax 
and the slight expansion of the tissue caused by imbibing. The tissue block was 
then sectioned at 5µm thickness. A gentle exhalation onto the block while 
cutting helped to alleviate the difficulty encountered in cutting a smooth flat 
section by expanding the block to give thicker sections. When a ribbon of 6 to 8 
sections were cut it was transferred to a preheated water bath at 37º C by 
holding the first section using a forceps and the last section was gently lifted 
away from the blade using the back of a small squirrel hair brush.  
Once floated in the heated water bath, the sections were separated from each 
other gently by using a fine pointed or curved forceps. The folds in the sections 
were rectified by gently teasing using a forceps and if unsuccessful such 
sections were discarded. Once separated, the sections were drawn on to a 
SuperFrost plus slide (SuperFrost, VWR) and were consecutively numbered. 
The slides were then held in a slide rack to drain the water and kept at 37º C for 
72 hours in an incubator.   
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2.3.2 Tissue micro array construction 
Most of the TMAs used (n =8) in the IHC analysis were already constructed 
(TMA 1 to TMA 7) (Shaaban et al., 2012) and I constructed one TMA as part of 
my research from FFPE blocks (n=18) received from collaborators in 
Portsmouth (TMA 8). FFPE blocks were sectioned at 5µm thickness and 
stained using haematoxylin and eosin method (H&E). The H&E stained sections 
were examined under the microscope (Olympus BX41) and tumour rich areas 
were marked using a fibre tipped permanent marker pen (Figure 1). 
Recipient paraffin TMA blocks were constructed using melted paraffin wax 
(Surgipath Formula R). The melted wax was poured on to plastic moulds 
(Dispomoulds, Cellpath) with the cassette inserted on top of the mould and was 
left at room temperature overnight to solidify. Once solidified, all recipient TMA 
blocks were routinely X-rayed and only those without any cracks or bubbles 
were used.  
A manual TMA instrument (MTA1, Beecher Instruments, USA) (Figure 2) was 
used for constructing the TMA.  The small punch of the instrument was used to 
construct a hole in the recipient TMA block and 0.6mm diameter cores were 
punched out from the donor blocks in triplicate to reduce sampling errors using 
the large punch. These cores were then inserted in to pre- made holes in the 
recipient TMA blocks. For thin donor blocks, multiple cores were stacked in to 
each recipient hole to create deeper cores. The donor cores were arranged in 
the recipient TMA block precisely according to a pre-determined TMA plan. For 
orientation purposes, we incorporated marker cores using miscellaneous  
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Figure 1:  H&E stained slide marked with tumour rich areas 
The inset represents magnified image of the marked area with breast cancer from 
where TMA core was taken subsequently. 
 
 Figure 2: Manual Tissue Microarray instrument  
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tissues (sheep liver, lung, brain) in the TMA plan. After construction, TMA block 
was kept in the incubator at 37ºC overnight to facilitate embedding of the 
grafted donor tissue cores into the recipient block. Once removed from the 
incubator TMAs were stored at 4ºC. TMA blocks were sectioned using a manual 
microtome (LeicaTM RM2235) and the cellularity of the TMA sections were 
measured using H&E staining of the first and last sections. The sections were 
placed on Superfrost plus slides (Superfrost, VWR) and serially numbered. The 
sections were then dried in an incubator at 37ºC overnight. In order to minimise 
potential loss of antigenicity, it was a routine practice to apply a layer of wax to 
cover the sections for storage at 4ºC. Sections stored under the above 
conditions were generally used for IHC within 90 to 120 days.  
  
32 
 
2.3.3 Immunohistochemistry 
Immunohistochemistry analysis was performed in the MBC TMAs (TMA 1 to 8) 
for 18 biomarkers (Table 2).  The IHC staining and scoring for ERα, Total PR, 
CK5/6, CK14, CK18, CK19, Bcl2, AR, ERβ1, ERβ2, ERβ5 and Her2 were 
performed by my predecessors (Shaaban et al., 2012) in TMAs 1 to 4, 6 and 7. 
Similarly the IHC analysis for E-cadherin and p53 were already performed in 
TMAs 1 to 5. During the conduct of the research project, I have completed the 
IHC analysis in the remaining TMAs and scored them for the above biomarkers. 
In addition, I performed the IHC and scoring for Survivin, Prolactin, FOXA1 and 
Ki67 in all the MBC TMA blocks.  
2.3.3.1 General steps  
TMA blocks were sectioned at 5 µm thickness and placed on Superfrost plus 
slides (Superfrost, VWR) prior to incubating at 37ºC overnight. The slides were 
then de-waxed by passing through a series of xylene (3x5 minutes), rehydrated 
through graded ethanol 100% (2x3 minutes), 90% (1x3 minutes) and 70% (1x3 
minutes) before washing in running tap water for 2 minutes. The slides were 
subjected to peroxidase block to inhibit endogenous peroxidase activity by 
immersing in 10% hydrogen peroxide (H2O2) (180 ml of methanol and 20 ml of 
H2O2) for 10 minutes. The slides were then washed in running tap water for 5 
minutes prior to heat induced antigen retrieval in a pressure cooker. The slides 
were placed in boiling 1% antigen unmasking solution (Vector Laboratories) and 
cooked at full pressure for 2 minutes. The slides were then immediately cooled 
under running tap water for 5 minutes. 
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Table 2: Antibody specification for immunohistochemistry 
Antibody  Clone Dilution Manufacturer Catalogue 
Number 
Secondary antibody detection 
method 
ER alpha  1D5 1:100 Dako M7047 DAKO Envision Kit (Anti-mouse) 
FOXA1 ab55178  1:500 Abcam ab55718 DAKO Envision Kit (Anti-mouse) 
Total PR PgR 636 1:200 Dako M3569 DAKO Envision Kit (Anti-mouse) 
CK5/6 D5/16 B4 1:100 Dako M7237 DAKO Envision Kit (Anti-mouse) 
CK14 LL002 1:500 BIO-RAD MCA890F DAKO Envision Kit (Anti-mouse) 
CK18 CY-90 1:500 SIGMA C 8541 DAKO Envision Kit (Anti-mouse) 
CK19 RCK 108 1:150 Dako GA615 DAKO Envision Kit (Anti-mouse) 
E- cadherin NCH-38 1:100 Dako M3612 DAKO Envision Kit (Anti-mouse) 
Ki67  MIB1 1:100 Abcam ab124929 DAKO Envision Kit (Anti-mouse) 
p53 DO-7 1:1000 Dako M7001 DAKO Envision Kit (Anti-mouse) 
Bcl2 124 1:200 Dako M0887 DAKO Envision Kit (Anti-mouse) 
Her-2 PN2A 1:25 Dako K5204 DAKO Envision Kit (Anti-mouse) 
Prolactin B6.2 1drop:3000 Thermo Scientific MA5-11955 DAKO Avidin/Biotin detection kit 
Survivin  D8  1:25 Santacruz sc-17779 DAKO Avidin/Biotin detection kit 
AR AR441 1:100 Dako M3562 DAKO Avidin/Biotin detection kit 
ER β1 PPG5/10 1:20 BIO-RAD MCA1974S 
Menarini diagnostic intellipath FLX 
autostainer 
ER β2 57/3 1:20 BIO-RAD MCA2279 
ER β5 5/25 1:50 BIO-RAD MCA4676T 
 
The heat induced antigen retrieval was performed in pressure cooker using Vector low 
pH antigen unmasking solution in all the biomarkers except for ERβ1, ERβ2 and ERβ5. 
The Access Revelation™ buffer solution was used for antigen retrieval in ERβ1, ERβ2 
and ERβ5. The primary antibody was incubated for one hour at room temperature for 
CK14, CK18, CK19, ERβ1, ERβ2 and ERβ5. The rest of the biomarkers were 
incubated with primary antibody overnight at 40C. The details of the scoring methods 
used for each biomarker is described in section 2.4.1 through to 2.4.4 (Page no. 44 to 
60) 
 
2.3.3.2 EnVision method  
After completion of the above steps, Shandon cover plates were applied to the 
slides prior to inserting it in to a Shandon Sequenza apparatus (Thermo 
Pharmaceuticals). The slides were washed initially with phosphate buffered 
saline (PBS) prior to subjecting to casein block to eliminate non-specific 
background staining. We used 10% of casein (Vector Laboratories) in PBS (100 
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µL per slide) for 20 minutes to achieve the casein block followed with one 5 
minutes wash with PBS. The slides were then incubated with the primary 
antibody at 100 µL dilutions overnight or for 1 hour.  Overnight incubation was 
done in a humid chamber at 4ºC, whereas 1 hour incubation was done at room 
temperature. The details of the primary antibody used for each biomarker, the 
concentration used and the incubation times are described in Table 2. In every 
batch, a positive control of FBC TMA was used and a negative control was run 
by incubating with PBS instead of primary antibody.  
After incubation with the primary antibody, the slides were washed with PBS 
(2x5 minutes) and 100 µL/slide of secondary antibody (Envision/HRP (DAKO)) 
was applied for 40 minutes. This was followed with a PBS wash (2x5minutes) 
and the slides were then removed from the sequencer to be placed on a humid 
tray. In order to visualise the reaction of the biomarker with that of the antibody, 
100µL of 3, 3’- diaminobenzidine (DAB) (Vector Laboratories) was applied to 
each section. After 10 minutes, the excess of DAB was removed from the slides 
and the sections were washed in running tap water for 2 minutes. The counter 
staining was performed by passing the slides through copper sulphate for 1 
minute, Mayer’s haematoxylin for 2 minutes and Scott’s substitute for 2 minutes. 
Each step was followed with washing the slides in running tap water for 1 
minute each. The sections were dehydrated by passing through absolute 
ethanol (1x10 seconds; 1x30 seconds; 2x5 minutes) and cleared using serial 
passage through xylene (3x2 minutes) before being mounted in DPX. 
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2.3.3.3 Access Revelation buffer solution  
Access Revelation™ buffer solution was used for both de-paraffinization and 
antigen retrieval in the pressure cooker for IHC staining of ERβ1, ERβ2 and 
ERβ5 in the intelliPATH FLX™ autostainer (Menarini diagnostic) (The 
immunostaining was performed by Mr Mike Shires, Laboratory Technician). It 
has several advantages as it is non-toxic, non-inflammable and odourless in 
comparison to alcohol and xylene. Moreover it reduces non-specific background 
staining, blocks the endogenous peroxidise and has a colour coded pH 
indicator.  
2.3.3.4 Avidin-Biotin method 
After completion of the antigen retrieval as described above, the slides were 
covered with Shandon cover plates prior to transferring in to a sequenza 
apparatus. The slides were washed with PBS for 5minutes. Subsequently, 2 
drops of Avidin solution (Vector Laboratories) (300µL/slide) were applied to the 
slides which were left at room temperature for 10 minutes. The slides were 
washed with PBS (2x5 minutes) before applying 2 drops of Biotin solution 
(Vector Laboratories) (300µL/slide) and were left at room temperature for 10 
minutes. This was followed by PBS wash (2x5 minutes) prior to the slides being 
incubated with the primary antibody (100µL/slide) diluted using the antibody 
diluent reagent (Invitrogen). The sections were left to incubate with primary 
antibody over night at 4ºC in a humid chamber.  
The next day, slides were washed with PBS (2x5 minutes) before applying 1 
drop (100µL/slide) of secondary antibody (ChemMate kit, DAKO, Bottle A). The 
slides were left at room temperature for 30 minutes before washing with PBS 
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(3x5 minutes). Subsequently, 1 drop (100µL/slide) of Avidin-peroxidase 
(ChemMate kit, DAKO, Bottle B) was applied for 30 minutes in the room 
temperature. The slides were then washed with PBS (3x5 minutes) before 
removing from the Sequenza apparatus. The visualisation of the antigen-
antibody reaction using the DAB chromogen and counter staining methods is 
similar to those described under the two-step Envision system. The Avidin-
Biotin method is schematically illustrated below in Figure 3.   
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Figure 3: Labelled Streptavidin-Biotin method 
Schematic represenation of streptaviding-biotin method. The multiple biniding sites 
between tetravalent avidin and biotinylated secondary antibody provides amplification 
for the reaction and hence improved sensitivity for detection of the tissue antigen. 
 
 
 
Figure 4: Aperio ImageScope™ 
A screen shot depicting various toolbars available to facilitate IHC scoring using the 
Aperio ImageScope™ software.  
          Biotinylated secondary antibody 
                    Primary antibody 
Tissue antigen 
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2.3.4 Antibody optimisation  
All antibodies used were initially tested in the laboratory using positive controls 
as depicted in the manufacturer’s specification sheet. It was a routine practice 
to note the concentration described within the literature or by the manufacturer 
as a reference point and to use a concentration above and below that for 
confirming the correct dilution of the antibody on whole tissue sections. The 
maximum dilution of the antibody which gave equivocal and best staining of the 
tissue antigen with least possible background and non-specific interaction was 
selected (Howat et al., 2014).  In order to ensure optimal results in TMAs, we 
ran the same experiment in identical conditions using small control TMA 
containing 10 FBC cores. Routinely we used antigen diluent reagent 
(Invitrogen) for diluting all the antibodies and PBS to wash the slides except in 
the case of Androgen receptor (AR), where we used 2% Tween 20 (Polysorbate 
surfactant). 
2.3.5 Immunohistochemistry scoring 
The TMAs once stained were scanned (ScanScope XT, Aperio) at 20x 
magnification.  The scanned slides were viewed and manually scored using 
ImageScope™ software (Aperio). The ImageScope™ as a software was easy 
to manoeuvre with various tool bars (Figure 4). The individual cores can be 
visualised using the pre-determined objective magnification at which the slides 
have been scanned (Figure 4). The provision of the “film strip” in a smaller 
window ensures that the user does not lose the orientation after magnification. 
The provision of axes and gridlines was especially useful when counting of the 
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individual nuclei was required e.g. for scoring Ki67 and Survivin. There are 
various other adjuncts that can be utilised during IHC scoring like the 
magnifying pane, thumbnail and snap shots for saving the images. 
2.3.6 Statistical analysis  
The clinical and pathological independent variables including, age at diagnosis, 
tumour size, grade, nodal status, LVI, and various biomarker expression were 
evaluated against overall survival (OS) as the dependent variable. The 
categorical and continuous variables were distinguished and appropriate 
statistical tests were performed. The distribution of the data was schematically 
checked using a histogram and normality tests were performed to determine the 
type of descriptive statistics required for continuous variables. A power 
calculation to determine the sample size was not possible due to rare nature of 
MBC as well as due to the retrospective and exploratory nature of the study.  
Pearson’s correlation coefficient was used for normally distributed continuous 
explanatory variables. A Spearman’s correlation coefficient was used if the 
distribution was non-parametric or if the variable was categorical. The measure 
of agreement was calculated using the κ statistics for categorical variables. The 
type of tests used for determining the measure of association between the 
variables was dependent on the outcome variable. The type of test used for 
each outcome is described explicitly in the results section.  
The strength of association between clinical and pathological variables, various 
bio-markers and primary outcome measure (OS) was ascertained using Cox 
logistic regression analysis. The prognostic variables that were significant on 
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univariate analysis were entered into a multivariate analysis model to identify 
independent predictors of OS at 5 and 10 year period.  The overall survival 
analysis was performed using a Cox proportional hazard model. The survival 
curves were plotted using the Kaplan-Meier method and compared using the 
Log rank test. The data was analysed using SPSS (Statistical Package for 
Social Sciences) version 19 software and a P value of ≤ 0.05 was considered 
as statistically significant.  
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2.4 RESULTS 
Immunohistochemical analysis was performed in TMAs constructed from 428 
MBC tissue blocks. Cores were missing in 19 patients which were excluded 
from the statistical analysis. The demographic details and/or tumour 
characteristics (tumour size/nodal status/TNM staging) were missing in 28 
patients. The follow-up data alone was not available for 37 patients. In another 
143 patients, demographic data, tumour characteristics and follow-up 
information was not available. Therefore, the final analysis of descriptive 
statistics, measure of association and correlation was performed in 238 patients 
(Figure 5). Similarly survival analysis was performed in 229 patients, in whom 
the follow-up data was complete (Figure 5). 
The median age of the cohort was 68 years (IQR = 17 years) (Figure 6). The 
tumour characteristics are summarised in Table.3. In more than three quarter of 
the patients the tumour was < 5 cm in size. The most common histological type 
was ductal cancer (88.2%), with only a small proportion being lobular (0.8%). 
The majority of the tumours were grade 2 or 3 and only 10% of the tumours 
were grade 1. Axillary nodal metastases were present in 53% of the cases. 
Amongst node positive cases (n=113), most were N1 (n=55, 48.6%) tumours. In 
comparison to FBC, early lympho-vascular invasion occurs in MBC due to the 
lack of distinctive tissue planes (Wagner et al., 1995, Contractor et al., 2008). 
However, metastatic involvement of axillary lymph nodes was only found in just 
over half of the cases and most had ≤ 3 involved lymph nodes.  
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Figure 5: Schematic representation of MBC samples included and excluded from 
analysis  
Total number of 
patients in whom TMA 
cores were available 
n = 428
Total number of 
patients available for 
analysis 
n = 409
In the remaining 
patients statistical 
analysis was 
performed
Total number of patients in 
whom descriptive or 
association analysis performed 
n = 238 [409 - 171(143 +28)] 
Total number of patients in 
whom survival analysis 
performed 
n = 229 [409 - 180(143+37)]
Clinical or pathological 
data missing 
n = 28 Both clinical or 
pathological & survival 
data missing 
n = 143 
Survival data missing 
n = 37
Missing cores 
n = 19
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Figure 6: Histogram depicting age distributions in the male breast cancer cohort 
 
 
 
Table 3: Histopathological characteristics of the MBC cohort  
Characteristics  Frequencies 
Tumour size (n = 208)  
T1 104 (50%) 
T2 91 (43.8%) 
T3 11 (5.3%) 
T4 2 (1%) 
Histological type (n = 238)  
Ductal  210 (88.2%) 
Lobular  2 (0.8%) 
Mixed  7 (3%) 
Special type 19 (8%) 
Tumour grade (n = 235)  
G1 24 (10.2%) 
G2 123 (52.3%) 
G3 88 (37.4%) 
Nodal status (n=223)  
Node positive  113 (51.1%) 
Node negative  99 (44%) 
No axillary surgery  11 (4.9%) 
TNM nodal status (n = 212)  
N1 55 (25.9%) 
N2 39 (18.4%) 
N3 19 (9%) 
Node negative 99 (46.7%) 
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2.4.1 Hormonal Biomarkers  
2.4.1.1 Oestrogen receptor α (ERα) 
The percentage of positive nuclear immunoreactivity as well as the intensity of 
the nuclear staining was considered for determining ERα expression (Allred et 
al., 1998). An Allred score of > 2 was considered positive for ERα expression 
(Shaaban et al., 2012). The ERα immunoreactivity was nuclear specific in our 
cohort and there was no background cytoplasmic staining observed (Figure 7a). 
ERα was positive in 212/226 cases (93.8%) and negative in the rest (14/226; 
6.2%).  
2.4.1.2 Oestrogen receptor β1 (ERβ1) 
Similar to ERα, both the percentage and intensity of the nuclear 
immunoreactivity was determined for ERβ1 using the Allred method (Allred et 
al., 1998). The ERβ1 staining was nuclear specific in most of the cases with 
mild to moderate background cytoplasmic staining (Figure 7b). Only nuclear 
staining was considered for determining the Allred score. Allred score of > 3 
was considered positive for ERβ1 expression (Shaaban et al., 2012). ERβ1 was 
positive in 166/218 cases (76.1%) and was negative in 52/218 cases (23.9%).  
2.4.1.3 Oestrogen receptor β2 (ERβ2) 
ERβ2 was scored using the Allred method accounting for both the intensity and 
percentage of nuclear staining (Allred et al., 1998). The staining was observed 
in the nuclei of epithelial cells and similar to ERβ1 there was mild background 
cytoplasmic staining observed in most of the TMA cores (Figure 7c). Allred 
score of > 3 was considered positive for ERβ2 expression  
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Figure 7: Expression of ERα, ERβ1, ERβ2 and ERβ5 in MBC 
a) Unequivocal nuclear staining of ERα. b) Nuclear staining of ERβ1 with mild 
background cytoplasmic staining. c) Nuclear staining of ERβ2 with mild to moderate 
background cytoplasmic staining. d) Nuclear staining of ERβ5 with mild background 
cytoplasmic staining. Inset – Illustration of 20x magnified image of the marked square 
depicted in the TMA core.  
Figure. 7a Figure. 7b
Figure. 7c Figure. 7d
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(Shaaban et al., 2012). ERβ2 was positive in 156/218 cases (71.6%) and 
negative in 62/218 (28.4%). 
2.4.1.4 Oestrogen receptor β5 (ERβ5) 
The Allred method was used for determining the immunoreactivity of ERβ5 
(Allred et al., 1998) and a score of > 3 was considered as positive (Shaaban et 
al., 2012). There was strong nuclear staining with mild to moderate background 
cytoplasmic staining observed in the MBC TMA cores (Figure 7d). Compared to 
other hormonal biomarkers, ERβ5 IHC was performed in a small cohort of our 
patients (n = 120) due to the exhaustion of the TMA. Similar to the other 
oestrogen receptors, most of the cases were positive for ERβ5 expression 
(97/120; 80.8%) and negative in the rest (23/120; 19.2%).  
2.4.1.5 Androgen receptor (AR) 
The Allred method was used for scoring AR expression (Allred et al., 1998) and 
a cut off of > 4 was considered as positive (Shaaban et al., 2012). The AR 
expression was nuclear specific with occasional background cytoplasmic 
immunoreactivity (Figure 8a). Compared to other hormonal biomarkers, AR was 
positive in 125/224 (55.8%) and was negative in the rest 99/224 (44.2%).  
2.4.1.6 Progesterone receptor (PR) 
The PR expression was nuclear specific in the cancer epithelial cells (Figure 
8b). The Allred scoring system was used for scoring PR and a cut off of > 2 was 
used for determining PR expression (Allred et al., 1998, Shaaban et al., 2012). 
PR was positive in 186/221 cases (84.2%) and negative in 35/221 (15.8%).  
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2.4.1.7 Prolactin 
The immunoreactivity of prolactin was seen in the cell membrane/cytoplasm of 
the cancer epithelial cells (Figure 8c). There was no immunoreactivity within the 
cancer cell nuclei or stromal elements. The intensity (1 = weak, 2 = moderate, 3 
= strong) and extent (0 = no staining, 1 = 1 to 10%, 2 = 11 to 40%, 3 = 41 to 
75% and 4 = >75%) of the staining was determined in each TMA core. The 
individual scores were then multiplied to obtain a score ranging from 0 to 12 and 
a score of > 3 was considered positive for prolactin expression (Bratthauer et 
al., 2010, Ferreira et al., 2008). In our cohort, prolactin was negative in most of 
the cases 148/219 (67.6%) and positive in the remaining 71/219 cases (32.4%). 
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Figure 8: Expression of AR, PR and Prolactin receptor in MBC TMA cores 
a) Unequivocal nuclear staining of AR in MBC. b) Nuclear staining of PR with mild 
background staining. c) Cytoplasmic membranous staining of prolactin. Inset – 
Illustration of 20x magnified image of the marked square depicted in the TMA core.  
Figure. 8a Figure. 8b
Figure. 8c
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2.4.2 Cytokeratins 
Analysis was undertaken for CK5/6, CK14, CK18 and CK 19 in the MBC cohort. 
Only unequivocal cytoplasmic and membranous staining in the cancer epithelial 
cells was considered for determining the cytokeratin expression (Simpson et al., 
2005). The cytokeratin staining was scored semi-quantitatively into 5 
categories; <5%, 5 to 25%, 26 to 50%, 51 to 75% and > 75% of the cancer 
epithelial cells stained. A score of 5% or above was considered as positive for 
cytokeratin expression in the MBC cohort.  
2.4.2.1 Cytokeratin 5/6 (CK5/6)  
The CK5/6 staining was detected only in the cytoplasmic and membranous 
compartment of the cancer epithelial cells (Figure 9a). Most of the cases were 
negative for CK5/6 (192/225; 85.3%) and positive in the rest (33/225; 14.7%).  
2.4.2.2 Cytokeratin 14 (CK14) 
Similar to other basal cytokeratin markers, only 4/221 (1.8%) cases were 
positive for CK14 and rest were negative (217/221; 98.2%). The CK14 staining 
was observed in the cancer epithelial cell cytoplasmic membrane. 
2.4.2.3 Cytokeratin 18 (CK18) 
The CK18 expression was positive in most of the MBC patients (217/225; 
96.4%) and negative in 8/225 cases (3.6%). The CK18 expression was specific 
for the cytoplasmic membrane in most of the cases (Figure 9b).  
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2.4.2.4 Cytokeratin 19 (CK19) 
The CK19 staining was observed only in the cytoplasmic membrane in the MBC 
cohort (Figure 9c). Similar to CK18, CK19 was positive in most of the MBC 
patients (211/218; 96.8%) and negative in 7/218 cases (3.2%).  
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Figure 9: Expression of cytokeratins in MBC TMA cores 
a) Cytoplasmic and membranous staining of CK5/6 (20x magnification). b) Cytoplasmic 
and membranous staining of CK18. c) Cytoplasmic and membranous staining of CK19. 
Inset – Illustration of 20x magnified image of the marked square depicted in the TMA 
core.  
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2.4.3 Proliferation and apoptosis markers 
2.4.3.1 Ki67  
The Ki67 IHC was performed adhering to the International Ki67 in Breast 
Cancer Working Group Consensus recommendations (Dowsett et al., 2011). As 
Ki67 is a proliferative marker, only unequivocal nuclear staining was considered 
for determining its expression in MBC tissue. Since the intensity of the nuclear 
staining was not shown to have any prognostic relevance, it was not determined 
while scoring the TMAs. In each TMA core a minimum of 500 cancer nuclei 
were counted and the percentage of DAB stained nuclei was determined. The 
Ki67 score was used as a continuous variable for descriptive analysis and for 
determining its association with other biomarkers and clinico-pathological 
prognosticators. However for survival analysis, the Ki67 score in percentage 
was dichotomised in to a high and low score. A score of ≥ 14% was considered 
as high, as it was determined against an important distinction in the underlying 
biology (Luminal A vs. Luminal B) compared to clinical outcomes or median 
Ki67 values as used in the past (Cheang et al., 2009).  
The background cytoplasmic staining with SP6 and MIB1 antibody for Ki67 has 
been previous described in the literature and acknowledged by the International 
Ki67 in Breast Cancer Working Group (Dowsett et al., 2011). The IHC for Ki67 
was initially performed using SP6 antibody which resulted in strong background 
cytoplasmic staining with mild to moderate patchy nuclear staining (Figure 10a). 
Hence, MIB1 antibody was used for Ki67 IHC in our MBC cohort. MIB1 antibody 
produced strong nuclear staining with moderate to strong  
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Figure 10: Expression of Ki67, Bcl2 and P53 in TMA cores 
a) Ki67 IHC using SP6 antibody in FBC TMA – Nuclear staining of Ki67 observed along 
with strong background cytoplasmic staining b) Unequivocal nuclear staining of Ki67 
using MIB1 clone of antibody in MBC TMA. c) Cytoplasmic and membranous staining 
of cancer cells by Bcl2 in MBC TMA d) Unequivocal nuclear staining of cancer cells by 
P53 in MBC TMA. Inset – Illustration of 20x magnified image of the marked square 
depicted in the TMA core.  
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intensity background cytoplasmic staining in our cohort (Figure 10b). It was 
noted that in most of the TMA cores only a proportion of the cancer nuclei were 
positive for Ki67. This could be due to the non-proliferative nature of the 
individual cells or the cell being in the G0 phase of the cell cycle during which 
Ki67 is not expressed.  Optimisation of the MIB1antibody using various dilutions 
was performed first in full section breast cancer tissue prior to optimising it in 
control TMAs to ensure unequivocal nuclear staining.  
The distribution of Ki67 expression in our entire cohort is depicted in Figure 11. 
The dichotomisation of Ki67 percentage score using a cut of ≥ 14% showed a 
high Ki67 expression in 63/202 cases (31.2%) and a low score in the rest 
(139/202; 68.8%). 
 
 
Figure 11: Histogram representing the distribution of Ki7 scores in the MBC 
cohort 
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2.4.3.2 Bcl2 
Bcl-2 (B-cell lymphoma 2) is the founding member of the family of proteins that 
regulate cellular death (apoptosis). In humans, it is encoded by the BCL2 gene, 
and it induces or inhibits apoptosis. The cytoplasmic membranous staining in 
the cancer epithelial cells was observed for Bcl2 (Figure 10c). A clear 
cytoplasmic membranous staining with a cut off of 10% was used for 
determining Bcl2 expression (Callagy et al., 2006). The Bcl2 IHC was 
performed only in 161 cases and couldn’t be performed in the remaining 77 
cases due to exhaustion of TMA cores. Bcl2 was positive in most of the MBC 
patients (152/161; 94.4%) and negative only in a small minority (9/161; 5.6%).  
2.4.3.3 p53 
The percentage of cancer epithelial cell nuclei with unequivocal nuclear staining 
was determined for p53 immunoreactivity. A score of > 10% of nuclear staining 
was taken as the cut off for positive p53 expression (Plesan et al., 2010). The 
nuclear staining was specific for p53 expression in the MBC tissues (Figure 
10d). Only in 42/214 cases (19.6%) p53 was positive and in the rest p53 was 
negative (172/214; 80.4%).  
2.4.3.4 Survivin 
The nuclear and cytoplasmic expression of survivin has been observed in 
breast cancer epithelial cells (Brennan et al., 2008, Al-Joudi et al., 2007, Younis 
et al., 2009). The initial attempts to optimise the survivin antibody (mouse 
monoclonal antibody – clone 12C4) were unsuccessful using envision, SAB and 
proteinase K methods. The nuclear staining was absent with envision method, 
whereas only patchy nuclear staining with background cytoplasmic staining was 
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observed with SAB and proteinase K methods. Hence a different clone (D8) of 
mouse monoclonal antibody was used in the MBC cohort, which has been 
previously validated in breast cancer tissue (Rexhepaj et al., 2010, Brennan et 
al., 2008). This antibody gave strong nuclear staining with background 
cytoplasmic staining which varied from weak to strong in the MBC cohort 
(Figure 12a – c). Both nuclear and cytoplasmic staining was considered for 
survivin. Nuclear staining was scored as the percentage of cancer epithelial 
cells with unequivocal nuclear staining (0 = < 5%, 1 = 5 to 20%, 2 = 21 to 50%, 
3 = 51 to 75% and 4 = > 75%) and a cut off of 5% was used as previously 
reported (Al-Joudi et al., 2007, Hinnis et al., 2007, Tanaka et al., 2000). 
Whereas, the intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong) and 
percentage (0 = < 5%, 1 = 5 to 20%, 2 = 21 to 50%, 3 = 51 to 75% and 4 = > 
75%) of cytoplasmic staining was determined. The individual scores for intensity 
and percentage of positive cancer epithelial cells with cytoplasmic staining were 
multiplied to produce a weighted score. Cases with a weighted score of ≥ 3 
were considered as positive for cytoplasmic survivin expression.  
The nuclear survivin was positive in 90/211 cases (42.7%) and negative in the 
rest (121/211; 57.3%). The cytoplasmic survivin was positive in most of the 
cases (193/211; 91.5%) and was negative only in a few cases (18/211; 8.5%).  
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Figure 12: Expression of survivin in MBC TMA cores 
a) Mild cytoplasmic expression of survivin. b) Moderate cytoplasmic and nuclear 
expression of survivin. c) Strong cytoplasmic immunostaining and nuclear expression 
of survivin. Inset - Illustration of 20x magnified image of the marked square depicted in 
the TMA core   
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2.4.4 Other biomarkers  
2.4.4.1 Human epidermal growth factor receptor 2 (Her2) 
The presence of Her2 was detected using the Hercep testTM (Dako). The 
percentage of cells with unequivocal membranous staining was determined 
(Figure.13a). Her2 was considered positive, when the score was 3+ on Hercep 
testTM test and Fluorescent in Situ Hybridisation (FISH) was performed in cases 
where Hercep testTM test showed a score of 2+ to confirm or refute Her2 
amplification (Figure 13b). The FISH test was performed by Mrs Barbara Ozlos, 
Biomedical Scientist at Leeds Teaching Hospitals NHS Trust. The presence of 
Her2 was evaluated only 178 cases due to the exhaustion of TMA core. Her2 
was negative in most of the cases 172/178 (96.6%) and positive in 6/178 cases 
(3.4%). 
2.4.4.2 E-cadherin  
The percentage of membranous staining was determined in each TMA core and 
a value of > 50% was considered as positive for E-cadherin expression (Callagy 
et al., 2006). The membranous staining was unequivocal in the MBC TMA cores 
with minimal background staining (Figure 13c). Most of the cases were positive 
for E-cadherin expression (161/212; 75.9%) and negative in only 51/212 
(24.1%).  
2.4.4.3 Forkhead box protein A1 (FOXA1) 
The expression of FOXA1 was observed in the nucleus of the cancer cells 
(Figure 13 d). A semi quantitative method was used for scoring FOXA1  
59 
 
 
Figure 13: Expression of Her2, E-cadherin and FOXA1 in MBC TMA cores  
a) Membranous staining of cancer nuclei with Hercep testTM. b) Fluorescent in Situ 
Hybridization showing Her2 amplification. c) Membranous staining of cancer cells with 
E-cadherin. d) Unequivocal cancer nuclear expression of FOXA1. Inset - Illustration of 
20x magnified image of the marked square depicted in the TMA core   
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(Badve et al., 2007). The intensity (0 = no staining, 1 = weak, 2 = moderate and 
3 = strong) and percentage of nuclear staining was determined in each TMA 
core (0 = no expression, 1 = 1-10%, 2 = 11-20% and so on to a maximum score 
of 10 = 91-100%). The scores were then multiplied to give a H-score ranging 
from 0 to 30. The FOXA1 score was considered as a discrete continuous 
variable for statistical analysis due to the semi-quantitative nature of the scoring 
method. The distribution of FOXA1 expression in the MBC cohort is depicted in 
Figure 14. The H-score was determined in 219 cases and the mean score was 
13.69 (SD±10.18). 
 
Figure 14: Bar chart showing distribution of FOXA1 scores in MBC 
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2.4.5 Measure of association  
2.4.5.1 Association between hormonal biomarkers 
There was strong positive association of ERα with that of AR (χ2 = 10.65; p = 
0.001) and PR (p = 0.0003, Fishers Exact test). In MBC cohort, there was no 
statistically significant association between ERα and ER β1 (p =0.57) or ER β2 
(p = 0.53), or prolactin (p = 0.25). There was no statistically significant 
association between ERβ subtypes. Amongst hormonal receptors, only AR was 
found to have a statistically significant positive association with ERβ1 (χ2 = 7.28; 
p = 0.007) and ERβ2 (χ2 = 13.87; p = 0.0001). There was no association 
between PR and AR or ERβ sub-types. Prolactin was the only hormonal 
marker, which didn’t have any statistically significant association with other 
hormonal markers. 
2.4.5.2 p53  
In our cohort only 20% of the cases were positive and rest were negative. The 
association of p53 with clinico-pathological variables and other biomarkers were 
explored to detect any significant result. There was no association between p53 
and clinico-pathological variables (Table 4).  
There was strong positive association between p53 and Ki67 (p = 0.002) in this 
cohort. However there was no statistically significant association with other poor 
prognosticators like grade or nodal status. Moreover, p53 was not shown to 
have any prognostic or predictive role in the overall survival of MBC patients 
(Table.5, Page no. 67 and Table.7, Page no. 68).  
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Variable Type of test P value 
Grade Linear-by-Linear association 0.142 
Tumour size Linear-by-Linear association 0.834 
Nodal status Linear-by-Linear association 0.969 
PR Pearson Chi-Square 0.103 
ERα Fishers’ Exact 0.741 
Bcl2 Fishers’ Exact 1 
Nuclear survivin  Pearson Chi-Square 0.944 
Cytoplasmic survivin Fishers’ Exact 1 
Ki67 Pearson Chi-Square 0.002 
 
Table 4: The association of p53 with clinico-pathological variables and 
biomarkers. 
 
2.4.5.3 ERα and Bcl2 
Bcl2 is an inhibitor of apoptosis as well as a target for oestrogen. Hence, the 
association between these biomarkers were explored in MBC. There was a 
strong positive association between ERα and Bcl2, (p = 0.034). This was in 
spite of doing analysis in a smaller sample size due to the exhaustion of TMA 
core allowing IHC of Bcl2 only in 161 cases. However, Bcl2 was not found to 
have any prognostic significance in this cohort. Considering the small sample 
size (n = 161), the lack of power might have prevented in identifying any true 
significance.  
2.4.5.4 Survivin  
There is substantial interest in the sub-cellular location of survivin due to its 
prognostic significance in various cancers (Li et al., 2005). There is only a single 
study so far in the literature, which explored the role of survivin in MBC without 
identifying any statistical significance (Younis et al., 2009). In this study, the 
sub-cellular location of survivin was determined and its relationship with various 
clinical and pathological markers was explored.  
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The nuclear survivin expression showed no association with grade (p = 0.49) or 
nodal status (p = 0.191). However, there was a weak association of nuclear 
survivin with tumour size categories (p = 0.034). Amongst hormonal biomarkers, 
only PR was found to have a positive association with nuclear survivin (χ2 = 
5.98; p = 0.014). Even though there was no association between nuclear 
survivin and grade of the breast cancer, there was a strong positive association 
with Ki67 expression (χ2 = 20.78; p = 0.001). Nuclear survivin didn’t show any 
association with Her2 (p = 1), Bcl2 (p = 0.134) and p53 (p = 0.944) 
In comparison to nuclear survivin, cytoplasmic survivin was positive in most of 
the cases (91%). There was no association with any of the clinical or 
pathological prognostic markers. However, there was a strong positive 
association with ERα (χ2 = 20.57; p = 0.001) and PR (χ2 = 8.41; p = 0.004). 
Similar to nuclear survivin, there was a statistically significant association 
between Ki67 and cytoplasmic survivin (χ2 = 8.68; p = 0.003). In this MBC 
cohort, neither nuclear nor cytoplasmic survivin was found to have any 
prognostic or predictive role. 
In FBC, the nuclear survivin was shown to be a poor prognosticator and a high 
cytoplasmic-to-nuclear ratio of survivin was shown to have better prognosis 
(Brennan et al., 2008). Brennan et al (2008) used automated in-house 
technology to perform consistent and reproducible survivin scoring. However 
with manual scoring of TMAs, It was not possible to reliably reproduce 
cytoplasmic-nuclear ratio in the MBC cohort. Future studies are needed to 
address the role of cytoplasmic-to-nuclear ratio of survivin in MBC using 
automated scoring.  
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2.4.6 Molecular subtypes in male breast cancer  
Based on gene expression profile, FBC has been classified in to intrinsic sub-
types with distinctive prognostic significance (Hu et al., 2006, Sorlie et al., 2003, 
Perou et al., 2000). The intrinsic subtypes described by Perou et al (2000) 
include Luminal A, Luminal B, Her 2 enriched and Basal or triple negative sub-
types. These tumour sub-types correlated well with survival and metastasis free 
outcome with Her2 and Basal types having the worse prognosis and Luminal A 
having the best overall outcome (Sorlie et al., 2003). It has been since then 
possible to use immunohistochemical biomarkers as surrogate for classifying 
FBC. Carey et al (2006) successfully managed to classify and replicate the 
prognostic significance of intrinsic FBC sub-types using an 
immunohistochemical panel consisting of ER, PR, Her2, CK5/6, CK14 and 
epidermal growth factor receptor (EGFR). In order to facilitate more accurate 
clinical classification of luminal B breast cancers, it has been proposed since 
then to include Ki67 to the immmunohistochemical panel (Cheang et al., 2009).  
In this cohort using surrogate biomarkers, MBC was classified in to the known 4 
FBC intrinsic sub-types. These include, Luminal A (ERα+ and/or PR+, Her2 & 
Ki67-), Luminal B (ERα+ and/or PR+, Her2-, Ki67+ or ERα+ and/or PR+, Her2 
+), Her 2 enriched (ERα -, PR – and  Her2 +) and Basal or triple negative breast 
cancer (ERα -, PR - & Her2 -). As described by Cheang et al (2009), a score of 
≥ 14% was considered as the ideal cut off for determining Ki67 positivity in this 
cohort. Amongst 238 cases available for analysis in the MBC cohort, molecular 
sub-types were determinable in 204 cases. Most of the cases were Luminal A 
(n=135; 66.2%), followed by Luminal B (n=62; 30.4%) and Basal or triple 
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negative sub-type (n=7; 3.4%). There was no Her2 enriched sub-type in the 
MBC cohort.  
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2.4.7 Regression analysis  
A logistic regression analysis was performed to determine predictors of survival 
in the MBC cohort. Cox regression analysis was performed using various 
clinico-pathological characteristics and biomarkers as explanatory variables and 
overall survival (OS) as outcome variable. The analysis was performed 
separately for 5 and 10 year OS.  
2.4.7.1 5 year OS 
On univariate analysis, grade, age and CK19 expression was found to be 
statistically significant (Table 5). Compared to grade 1 MBC cases, those with 
grade 2 were shown to have poor OS (OR = 0.368; p = 0.024 (CI = 0.15 to 
0.88). However, there was only a trend towards better survival amongst grade 1 
MBC cases compared to grade 3 (OR =0.756; p = 0.507 (CI = 0.33 to 1.73). 
This might have occurred due to the relatively small number of cases with grade 
1 and grade 3 cancers in this cohort compared to grade 2 MBC. There was a 
trend towards statistical significance with nodal status (p = 0.089), CK18 (p = 
0.068) and Ki67 (p = 0.078). Variables with statistical significance or trend 
towards significance were entered in to the multivariate analysis model. The 
results showed that only age and nodal status were retained in the model 
(Table 6) and found to be independent predictors of survival. 
2.4.7.2 10 year OS  
Consistent with 5 year OS results, both age and CK19 was found to be 
statistically significant on univariate analysis (Table 7). The results showed loss 
of survival predictability for nodal status in the MBC cohort with longer follow-up. 
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Hence the observed 5 year OS predictive role for nodal status could have been 
due to chance or not having sufficient power (due to sample size) to detect a 
true effect. The model for multivariate analysis was created using variables that 
were shown to have significance or trend towards significance in the 10 year 
OS analysis. The results showed only age to be an independent predictor for 
MBC OS (OR = 1.065 (CI – 1.04 to 1.1); p = < 0.001).    
Variable  HR (CI) p value 
Age  1.073 (1.04 - 1.11) 0.001 
Grade 1  0.04 
Grade 2 0.368 (0.15 - 0.88) 0.02 
Grade 3 0.756 (0.33 - 1.73) 0.5* 
Nodal status 1.885 (0.91 – 3.91) 0.09* 
ERα 3.002 (0.41 – 21.89) 0.278 
ER β1 0.600 (0.30 – 1.19) 0.145 
Erβ2 0.817 (0.38 – 1.75) 0.602 
ER β5 1.225 (0.42 – 3.59) 0.711 
PR 1.210 (0.47 – 3.11) 0.692 
AR  0.648 (0.34  - 1.25) 0.194 
Prolactin 0.711 (0.33 – 1.52) 0.378 
CK5/6 1.119 (0.40 – 3.16) 0.832 
CK14 2.148 (0.29  – 15.68) 0.451 
CK19 0.263 (0.10 – 0.68) 0.006 
CK18 0.334 (0.10 - 1.09) 0.068* 
*Ki67 1.825 (0.93 - 3.57) 0.078* 
Bcl2 1.819 (0.25 – 13.39) 0.557 
p53 1.037 (0.40 – 2.69) 0.941 
Nuclear survivin 1.634 (0.85 – 3.15) 0.143 
Cytoplasmic survivin 0.743 (0.26 – 2.10) 0.575 
Her2 3.316 (0.45 – 24.49) 0.240 
E-cadherin 1.326 (0.55 – 3.20) 0.531 
FOXA1 0.995 (0.96 – 1.03) 0.743 
 
Table 5: Cox univariate regression analysis result for 5 year overall survival in 
MBC cohort 
The variables in bold were found to be significant. * represents variables that were 
found to have a trend towards significance and entered in to the multivariate modelling. 
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Variable  
Multivariate analysis - 5 year OS 
OR (CI) p value 
Age  1.072 (1.03 - 1.12) 0.001 
Nodal status 2.369 (1.05 - 5.36) 0.04 
 
Table 6: Cox multivariate regression analysis result for 5 year overall survival in 
MBC cohort  
 
Variable  OR (CI) p value 
Age  1.061 (1.035 – 1.089) 0.0001 
Grade 1  0.113 
Grade 2 0.537 (0.27 – 1.08) 0.080* 
Grade 3 0.630 (0.42 – 1.69) 0.630 
Nodal status 1.357 (0.78 – 2.35) 0.277 
ERα 1.861 (0.58 – 5.93) 0.294 
ER β1 0.740 ( 0.43 – 1.27) 0.276 
ERβ2 0.794 (0.44 – 1.42) 0.438 
ER β5 0.816 90.39 – 1.72) 0.593 
PR 1.044 (0.54 – 2.00) 0.897 
AR  0.891 (0.54 – 1.47) 0.650 
Prolactin 0.764 (0.42 – 1.37) 0.370 
CK5/6 0.582 (0.21 – 1.60) 0.295 
CK14 1.026 (0.14 – 7.41) 0.980 
CK19 0.284 (0.12 – 0.67) 0.004 
CK18 0.675 (0.21 – 2.15) 0.506 
Ki67 1.312 (0.76 – 2.26) 0.330 
Bcl2 1.794 (0.44 – 7.37) 0.418 
p53 0.839 (0.40 – 1.77) 0.646 
Nuclear survivin 1.179 (0.71 – 1.96) 0.524 
Cytoplasmic survivin 1.137 (0.45 – 2.84) 0.783 
Her2 1.667 (0.23 – 12.13) 0.614 
E-cadherin 1.639 (0.81 – 3.33) 0.171 
FOXA1 1.005 (0.98 – 1.03) 0.711 
 
Table 7: Cox univariate regression analysis result for 10 year overall survival in 
MBC cohort 
The variables in bold were found to be significant. * represents variables that were 
found to have a trend towards significance and entered in to the multivariate modelling. 
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2.4.8 Survival analysis 
The data for OS was available for this MBC cohort. The Cox proportional 
hazard model was used for performing survival analysis and Kaplan-Meier 
survival plots were produced separately for 5 and 10 year OS. The 5 year OS 
analysis showed CK18 (p = 0.05) and CK19 (p = 0.003) to be statistically 
significant (Figure 15a & b).  There was a trend towards statistical significance 
with Ki67 (p = 0.07) and nodal status (p = 0.082) (Figure 16a & b). The results 
also showed statistically significant survival advantage for grade 2 MBC over 
other grades (p = 0.034). This could have occurred as a result of small number 
of grade 1 cases in the MBC cohort (n = 29), leading to lack of power to 
determine any statistically significant outcome. This was further affirmed, when 
10 year OS analysis was performed and only CK19 was shown to be 
statistically significant (p = 0.002) (Figure 17).   
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Figure 15: Kaplan-Meier survival curve at 5 years for CK18 and CK19  
Statistically significant poor OS at 5 years for (a) CK18 and (b) CK19 negative male 
breast cancers. Patients were censored when they ceased to be followed up for any 
reason but had not died due to breast cancer.   
Figure. 15a
Figure. 15b
71 
 
 
Figure 16: Kaplan-Meier survival curve at 5 years for Ki67 and nodal status 
A trend towards statistical significance was observed for (a) Ki67 and (b) nodal status 
at 5 years in the male breast cancer cohort. Patients were censored when they ceased 
to be followed up for any reason but had not died due to breast cancer.   
Figure. 16b
Figure. 16a
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Figure 17: Kaplan-Meier survival curve at 10 years for CK19 
Survival curve showing statistically significant poor 10 year overall survival for CK19 
negative male breast cancer patients. Patients were censored when they ceased to be 
followed up for any reason but had not died due to breast cancer.   
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2.5 DISCUSSION 
Even though there has been an increase in the incidence of MBC, it remains a 
rare cancer compared to FBC (CRUK, 2012). The low incidence of the disease 
results in a paucity of research compared to FBC. The current management of 
MBC is mostly transcribed and extrapolated from the information that is 
available from research undertaken in FBC. An attempt was made here to 
understand the biology of MBC using immunohistochemical analysis of various 
biomarkers.  
A high expression of ERα and PR was seen in this MBC cohort (93.8% and 
84.2% respectively). Similar higher expression of steroid receptors in MBC 
compared to FBC has been observed by other researchers (Contractor et al., 
2008, Shaaban et al., 2012). It has been hypothesised that, an up-regulation of 
the steroid receptors in an oestrogen depleted environment may be responsible 
for this (Muir et al., 2003). However, in comparison to FBC, ER α was not found 
to have any prognostic significance in MBC. This was further substantiated by a 
recent study combining data from copy number variation and gene expression 
demonstrating that even though most MBC are ER positive, they share features 
of ER negative FBC (Johansson et al., 2013). The different hormonal milieu in 
which male and female breast cancer develop could be another factor 
influencing gender specific prognostic significance of ERα. Finally, the high 
positive expression of ERα in MBC necessitates the need for large studies with 
sufficient power to detect any true prognostic effect.  
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The functional studies in MBC have shown a greater role for AR compared to 
ER (Weber-Chappuis et al., 1996b). However, AR expression in MBC has been 
variably reported within the literature ranging from 0 to 95% (Contractor et al., 
2008). Around 55% of the cases were AR positive in this MBC cohort, but did 
not add to prognostic significance. This finding further confirms the lack of a 
definitive prognostic role for hormonal receptors in MBC compared to FBC 
based on the current published literature.  
It has been shown that, in an oestrogen depleted environment, such as in post-
menopausal women or MBC, up-regulation of ER can lead to an increased 
response to oestrogen targets such as Bcl-2 (Nahleh and Girnius, 2006). Once 
up-regulated, Bcl-2 can lead to malignant transformation through genomic 
modification and downstream target activation (Muir et al., 2003, Rayson et al., 
1998). Even though Bcl-2 was shown to be over expressed in MBC compared 
to FBC (Muir et al., 2003, Rayson et al., 1998, Weber-Chappuis et al., 1996b), 
its prognostic significance remains uncertain. In this study, 94% of the cases 
were Bcl2 positive and there was a strong positive association between ER α 
and Bcl2 (p = 0.03). However, regression analysis did not reveal any statistically 
significant prognostic role for Bcl2 in this cohort of MBC (Tables 5 and 7, Page 
67 and 68 respectively).  
The high throughput gene expression studies have classified FBC into 
distinctive intrinsic sub-types with prognostic significance (Hu et al., 2006, Sorlie 
et al., 2003, Perou et al., 2000). It was possible to represent these intrinsic sub-
types with distinct prognostic significance using surrogate biomarkers 
immunohistochemically in FBC (Carey et al., 2006, Nielsen et al., 2004). 
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Therefore an attempt was made to evaluate the established FBC sub-types in 
this MBC cohort. The results showed a distinctive pattern with most MBC being 
either luminal A or luminal B subtype with no Her2 enriched subtype. Similar 
findings were observed by other researchers evaluating FBC subtypes in MBC 
(Abreu et al., 2016, Shaaban et al., 2012, Kornegoor et al., 2012). Recent 
evidence through high throughput gene expression profiling has confirmed the 
existence of unique MBC intrinsic subtypes, luminal M1 and M2 (Johansson et 
al., 2012, Johansson et al., 2011). The male subtypes did not cluster along with 
the known FBC subtypes. However unlike FBC, it has not been yet possible to 
represent these intrinsic subtypes immunohistochemically in MBC. The above 
evidence further substantiates that, MBC should be considered as a different 
molecular entity compared to FBC.  
The expression of various cytokeratins depends on their differentiation with 
CK5/6 & CK14 representing the basal/myoepithelial cells and CK18/CK19 that 
of luminal cells (Ciocca et al., 2006). The basal cytokeratin expression in MBC 
was quite low, with CK5/6 positive in 14% of cases and CK14 in only 1.8% 
cases. Conversely, most of the MBC cases (around 96% for CK18 and CK19) 
were positive for luminal cytokeratins. Similar high expression of luminal 
cytokeratins was shown in a smaller MBC cohort (n = 32) (Ciocca et al., 2006). 
Even in FBC, the expression of CK19 was shown to be in the range of 89 - 94% 
(Shao et al., 2012, Delgallo et al., 2010). CK19 negativity has been correlated 
with poor prognostic factors like ER/PR negativity and positive Ki67 expression 
in FBC (Fujisue et al., 2012). CK19 negativity was also found to be an 
independent predictor of poor overall survival and local recurrence in young 
women (Parikh et al., 2008). A similar finding was observed in this cohort of 
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MBC patients with CK19 being a predictor of OS on univariate analysis (p = 
0.006). Similarly, both CK18 and CK19 positive patients were found to have a 
statistically significant better OS (Results section: Figure 15a & 15b, Page no. 
70 and Figure 17, Page no. 72).  
In this cohort, age seems to be the single most statistically significant predictor 
of OS. However, its clinical significance could be of uncertain nature for the 
following reasons. The OS could have been influenced by various factors in a 
cohort with median age of 68 years. The varying length of patient follow-up due 
to the data originating from multiple centres around the world could have 
influenced the results. Finally, the retrospective nature of the study could have 
introduced selection and analytical biases influencing the results. However, it 
should be emphasized that, within these limitations, this series has got the 
second largest sample of MBC patients with adequate follow-up data within the 
published literature.  
The preliminary results of the International Male Breast Cancer Program which 
has got the largest number of MBC patients to date was recently presented at 
the San Antonio Breast Cancer Symposium (Cardoso, 2014). Amongst 1483 
eligible MBC patients with a median age of 68.4 years, ERα was positive in 
99%, PR positive in 81% and 97% were AR positive. Her2 was positive in 9% of 
the MBC patients, compared to 3.4% of the patients in this cohort. Ki67 was 
positive in 39% of the patients and was comparable to the expression levels 
noted in this cohort (31.2%).  The researchers didn’t identify any prognostic role 
for grade, Her2, AR, Ki67 and FBC surrogate subtypes in MBC patients. They 
showed better OS for MBC patients with high expression of ERα and PR (Allred 
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score of 7 or 8) compared to low expression (Allred score 3 to 6). However due 
to low percentage of ERα (1%) and PR (19%) negativity they could not test the 
OS in this group compared to Allred positive (score 3 to 8) group of MBC.  
The nodal status was found to be an independent predictor of OS at 5 years. 
However, the predictability was lost at 10 year OS analysis, indicating that it is 
not a reliable variable to predict long term survival in MBC. Amongst all 
biomarkers only CK19 was found to be an independent predictor for 5 year OS. 
However, its independent predictability was lost when the analysis was 
performed at 10 years. The effect of attrition due to longer follow-up, small 
number of CK19 negative cases, the sample size and power of the study were 
some of the factors that might have influenced the results. 
Survival analysis performed using Cox proportional hazard model showed 
statistically better 5 year OS for CK18 and CK19 positive MBC cases (Result 
section: Figure 15a & 15b, Page no. 70 and Figure 17, Page no. 72). However, 
only CK19 was shown to be statistically significant at 10 year follow-up. There 
was also a trend towards statistical significance at 5 year OS analysis with Ki67 
(p = 0.07) and nodal status (p = 0.082). Even though there was no OS benefit 
identified for Ki67, there was poor relapse free survival amongst node positive 
patients in the International Male Breast Cancer Program (Cardoso, 2014). 
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2.5.1 Limitations of the study  
Before summarizing and interpreting the findings, it is important to consider 
some of the limitations of this study. The retrospective nature of the study may 
have introduced biases. However considering the low incidence and prevalence 
of MBC, other methodologies would have been time consuming and impractical. 
A criticism is the missing clinical, pathological and follow-up data in 
approximately 40% of the patients reducing the power of the study. The lack of 
information about the surgical and adjuvant treatment given along with variation 
in the treatment modalities by virtue of the diverse sample should have 
confounded the outcome variable. However, the diverse nature of origin of the 
MBC tissue samples from various geographical areas around the world does 
indeed increases the external validity of the results.  
 
The primary outcome variable was OS, due to the lack of data on breast cancer 
specific survival (BCSS). The latter should have improved the internal validity 
and reproducibility of the findings. The findings of this study should be 
considered along with the advantages and disadvantages of TMA as a tool for 
histopathological evaluation in large number cancer cases. The benefits and 
disadvantages of tissue microarray as a tool for histopathological evaluation 
have been described extensively in the literature (Ilyas et al., 2013). In this 
cohort, TMA cores were missing only in 19 cases, which was acceptable 
considering the diverse nature of this cohort. The multitude of biomarkers 
evaluated in this study resulted in TMA exhaustion, which affected the 
evaluation of some of the biomarkers more than others.   
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2.6 CONCLUSION 
The study showed potential prognostic role for epithelial cytokeratins, especially 
for CK19 and to some extent for CK18 in MBC patients. However age was 
shown to be the single most independent predictor for survival in the MBC 
cohort. The study confirmed that the FBC molecular sub-types represented 
using surrogate biomarkers are expressed differently in MBC. Moreover the 
expression profile and role of biomarkers with known prognostic significance in 
FBC was shown to be different in this MBC cohort. Overall the findings of the 
study suggest inherent differences amongst male and female breast cancer at 
protein level. However, it also emphasizes the need for future studies with 
larger sample size and adequate follow-up. This will help in the identification of 
clinically relevant protein biomarkers that can be used in the management of 
MBC.
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CHAPTER 3
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3 External Validation of 
ImmunoRatio™ Image Analysis 
Application for ERα and Ki67 
Determination in Breast Cancer 
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3.1 INTRODUCTION 
Automated IHC image analysis systems were introduced in the early 1990’s 
with the intention to produce consistent, accurate and reproducible results 
without potential human errors associated with manual microscopic analysis 
(Kirkegaard et al., 2006). However it is only in the last few years that software 
has been developed for the assessment of high-throughput automated 
assessment of the histological slides. The majority of automated IHC analysis 
software’s are only available commercially and therefore its academic or clinical 
availability is limited to a few centres. Automated IHC image analysis systems 
are either fully or semi-automated but usually require input from the pathologist 
to delineate the areas to be evaluated.  
A fully or semi-automated IHC image analysis systems could be effective when 
scoring large cohort of histological samples. An automated image analysis 
system can reduce the time required to score more than 1000 TMA cores (428 
cases in triplicate) as in this MBC cohort. Another advantage is the consistency 
(by reducing inter and intra-observer variability) with which IHC scoring can be 
performed in a large cohort cases. However there is no single platform that can 
be utilised for scoring a range of nuclear, cytoplasmic and membrane 
biomarkers as evaluated in this MBC cohort. The availability of a common 
platform should have also helped in calculating the cytoplasmic-to-nuclear ratio 
of survivin (Brennan et al., 2008) in the MBC cohort.  
ImmunoRatio™ is a web based freely available fully automated IHC image 
analysis software developed for the evaluation of nuclear proteins, ERα, PR and 
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Ki67 (Tuominen et al., 2010). Even though the free web based platform 
improves the accessibility, similar to other fully automated platforms, the role of 
ImmunoRatio™ is limited to the analysis of IHC in tissue microarrays. In this 
study it was decided to evaluate the automated scoring of ERα and Ki67 using 
ImmunoRatio™ software in breast cancer TMAs. ERα was selected as a 
paradigm as it provides unequivocal nuclear staining with antibodies in clinical 
use and has got a well-established scoring method that has been in use over 
many years. Moreover, ERα is predictive for response to adjuvant hormonal 
treatment (Osborne, 1998) and around 70% of breast tumours are ERα positive 
(Murphy and Watson, 2002).  
The ability of cancer to proliferate uncontrollably (Hanahan and Weinberg, 
2011) can be evaluated immunohistochemically by measuring the expression of 
proliferative biomarkers. Antigen KI-67 (Ki67) is a nuclear protein that in 
humans is encoded by the MKI67gene and is the most well established 
proliferative marker in breast cancer (Dowsett et al., 2011). Ki67 is currently 
considered as the assay of choice for measuring tumour proliferation in clinical 
trials (Dowsett et al., 2011). However, Ki67 has proven to be a more challenging 
nuclear biomarker to analyse using automated systems (Mohammed et al 2012; 
Fasanella et al 2011). Hence, Ki67 was chosen as the second biomarker to be 
evaluated using the ImmunoRatio™ software in this study.    
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3.2 AIM 
The aim was to externally validate ImmunoRatio™ image analysis software in 
the determination of ERα and Ki67 expression in a pre-stained series of breast 
cancer TMAs. The ERα expression was evaluated in consecutive 100 cases of 
male and female breast cancer TMAs and Ki67 in 64 cases of male breast 
cancer TMAs.  
The objectives were to: 
1) Determine the agreement between manual and ImmunoRatio™ scoring 
2) Establish the practical applicability of ImmunoRatio™ software for 
scoring nuclear biomarkers  
(Work presented in this chapter has been published and details can be found in 
appendix 7, Page no. 188)  
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3.3 METHODOLOGY 
The TMAs that were pre-stained with ERα and Ki67 antibodies were selected 
from the Leeds Breast Research Group tissue archived at the Leeds Institute of 
Cancer and Pathology. Consecutive male (n=100) and female (n=100) breast 
cancer TMAs without any artefacts or missing cores were used for the 
evaluation of ERα. For the evaluation of Ki67, only MBC TMAs was used as per 
the recommendation of the International Ki67 in Breast Cancer Working Group 
(Dowsett et al., 2011).  This was due to the following reasons: It is well 
established that non-nuclear and multi-compartmental IHC staining can reduce 
the sensitivity of automated image analysis systems (Bolton et al., 2010). The 
SP6 antibody used for the evaluation of Ki67 in the FBC produced moderate to 
strong background cytoplasmic staining compared to the MIB1 antibody used in 
the MBC cohort. Hence from a cohort of 428 MBC cases, only 64 cases with 
unequivocal nuclear staining with weak or no background cytoplasmic staining 
were selected (Figure 18). Ethical approval for the use of male and female 
breast cancer tissues were obtained from the Leeds West (06/Q1205/156) and 
East (06/Q1206/180) Research Ethics Committees respectively. These TMA 
cores were made in triplicate from formalin fixed paraffin embedded cancer 
blocks as described previously (Hamilton-Burke et al., 2010, Shaaban et al., 
2012) in the methodology section (Chapter 2, Methodology section 2.3, Page 
no. 27-31).  
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3.3.1 Immunohistochemistry 
Immunohistochemistry for ERα and Ki67 was performed using standard 
published protocols as previously described (Chapter 2, Methodology section 
2.3, Page no.32-36). The stained slides were scanned at x 20 objective 
magnification using Aperio  
 
 
 
Figure 18: Ki67 immunohistochemistry staining with MIB1 antibody 
Ki67 IHC using MIB1 antibody showing unequivocal nuclear staining with weak 
background cytoplasmic staining (20x magnified image)  
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ScanScope™ and then visualised for manual scoring using the ImageScope™ 
viewing software. The manual scoring was performed under guidance of a 
consultant breast histopathologist (AMH). The Allred method (Allred et al., 
1998) was used for ERα manual scoring. In each TMA core, all representative 
cancer nuclei were counted and the proportion of unequivocally DAB stained 
nuclei were estimated for Ki67 manual scoring (Dowsett et al., 2011).  
3.3.2 ImmunoRatio™ software  
The ImmunoRatio™ software calculated the percentage of DAB stained nuclei 
area over the total nuclear area for each biomarker and represented it as 
Labelling Index (LI) (Tuominen et al., 2010). The software uses the uploaded 
microscope image, optional blankfield correction and threshold adjustment 
parameters entered into the website for determining the LI. The blank field 
image or an in-built algorithm (when it was not available as in the basic mode) 
was used for correcting illumination and colour balance. The corrected image 
was then separated into DAB and haematoxylin stained components using the 
colour deconvolution method. Subsequently each of the component area was 
subjected to threshold adjustments using the parameters entered in to the 
website (advanced mode) or using adaptive IsoData thresholding method (basic 
mode). The nucleus segmentation was then performed in the components to 
delineate the nucleus from other cell types. Once the nuclear area was defined 
within the DAB and haematoxylin stained components, the images were 
overlaid on each other to calculate the percentage of DAB stained area. The 
final output displayed both the input image and the colour de-convoluted image 
produced by the software to calculate the labelling index (Figure 19). 
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Figure 19: Schematic representation of various steps involved in the processing 
of uploaded image in the ImmunoRatio™ software 
The figure shows the use of colour deconvolution algorithm which separates DAB 
stained nuclei from haematoxylin counter stain followed by adaptive thresholding to 
allow nuclear segmentation (Figure obtained with permission from Tuominen et al. 
(Tuominen et al., 2010)) 
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3.3.3 Image acquisition and evaluation using ImmunoRatio™  
The pictures of the representative TMA core in its entirety were taken using the 
camera function available in the ImageScope™ software. The captured image 
was then saved in a JPEG file that was combatable for uploading into the 
ImmunoRatio™ web based analysis software. The individual JPEG files were 
uploaded in to the ImmunoRatio™ website for analysis (Figure 20). The 
software allows the option of analysing the uploaded image in either the basic 
or advanced mode. In the advanced mode, it offers the option for blank field 
correction, alteration of image scale and one can also adjust for the threshold of 
the brown and blue stained nuclei. Once the representative mode was selected, 
the software calculates the percentage of DAB stained nuclear area over the 
total nuclear area in the representative TMA core as the LI (Figure 21). The 
software gives the option of saving the images into the computer from their 
website for future reference.  
3.3.4 Statistical analysis  
The variation between the manual and ImmunoRatio™ scoring was analysed 
using Spearman’s and Pearson’s correlation for categorical and continuous 
variables respectively. The measure of agreement was calculated using Kappa 
statistics for categorical variables with a κ of 0.40 -0.59 considered as moderate 
agreement, 0.60-0.79 as good agreement and ≥ 0.80 as very good agreement 
(Landis and Koch, 1977). A weighted Kappa was calculated using the R 
package “psy” (Performed by Dr Helene Thygesen). The CI was then computed 
using Efron’s bias-corrected and accelerated (BCa) method based on 10,000 
bootstrap samples (Efron, 1987). The measure of agreement for a continuous 
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variable was determined using the Bland-Altman plot. The remaining statistical 
analysis was performed using SPSS version 19 (SPSS, Chicago, IL, USA).  
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Figure 20: JPEG image of ERα stained TMA core after uploading in to the 
ImmunoRatio™ website 
 
In this screen shot, the website is asking to select the size (blue circles seen at the 
bottom of the image) of the ERα stained nuclei prior to calculating the Labelling Index 
(LI). 
 
Figure 21: Illustration of Labelling Index calculated by ImmunoRatio™ software  
 
Example of Labelling Index (LI) calculated by ImmunoRatio™ for ERα in one the TMA 
cores (LI =8.4%). The “original image” refers to the image uploaded to the website & 
“Pseudo-coloured image” represents the colour deconvoluted image produced by the 
ImmunoRatio™ software. In the latter image, DAB stained areas are represented with 
brown staining and the blue areas correspond to haematoxylin stained cancer nuclei.  
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3.4 RESULTS 
3.4.1 ERα 
The ImmunoRatio™ software calculates the LI, which only accounts for the 
proportion of the stained nuclei. However the current gold standard for scoring 
ERα, the Allred score is a sum of the proportion and intensity of staining (Allred 
et al., 1998). The pre-stained TMA series in our cohort were scored using the 
Allred method. To allow a comparison with ImmunoRatio™, these scores was 
converted such that only the proportion of DAB stained nuclei were considered 
for comparison (Table 8). 
Allred score for proportion 
of stained cancer nuclei 
Equivalent ERα manual score Equivalent ImmunoRatio™ 
ERα scoring 
Negative 0 0 
1 1/100 0 to 1% 
2 1/10 >1% but ≤ 10% 
3 1/3 > 10 but ≤ 33% 
4 2/3 > 33 but ≤ 66% 
5 1 > 66% up to 100% 
 
 
Table 8: Manual and ImmunoRatio™ ERα scores converted into categories to 
assist analysis 
The median age for breast cancer diagnosis was 58.5 years (IQR = 27) 
amongst women compared to 70.5 years (IQR = 18) for men in our ERα cohort. 
Manual scoring showed ERα negative (Allred score = 0) in 43 cases, whereas 
26 cases were negative with ImmunoRatio™ (Table 9). There was excellent 
correlation between the manual and ImmunoRatio™ ERα IHC scoring 
(Spearman’s correlation = 0.872; p = 0.000). We observed only a moderate  
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Figure 22: Schematic representation of the inability of the ImmunoRatio™ 
software to differentiate cancer nuclei from stromal elements 
                                                                                
                       Figure. 22a                                                                                Figure. 22b 
a) The original ERα immunohistochemistry image saved in the JPEG format; b) The 
same image after colour deconvolution by ImmunoRatio™ software. The inability of the 
software to differentiate true cancer nuclei (C; coloured brown) from the stromal 
elements (A and B) is depicted. 
 
Figure 23: Correlation between manual and ImmunoRatio™ Ki67 proliferation 
index 
 
Scatter plot showing the correlation between manual and ImmunoRatio™ Ki67 
proliferation index. (Pearson correlation = 0.675, p = <0.001) 
A 
B 
C 
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Table 9: Comparison of manual and ImmunoRatio™ ERα scores 
 ImmunoRatio™ ERα Total 
0 1 2 3 4 5 
 
M
an
u
al
 E
R
α
 0 24 5 14 0 0 0 43 
1 0 0 4 0 0 0 4 
2 2 1 10 0 0 0 13 
3 0 0 5 13 4 1 23 
4 0 0 1 27 21 10 59 
5 0 0 0 3 16 39 58 
Total 26 6 34 43 41 50 200 
 
agreement (κ = 0.421) between the manual and ImmunoRatio™ scores. This 
may have been due to the underestimation of the ImmunoRatio™ LI score due 
to the inability of the software to differentiate cancer nuclei from the non-cancer 
stromal elements (Figure 22).  
The weighted Kappa was 0.874 (CI - 0.839 to 0.902) and was calculated using 
absolute weights (i.e. disagreements are weighted by the absolute difference 
between the automated and manual scoring). The discrepant cores were re-
evaluated to ensure that there were no human errors in the manual scores and 
it was reproducible. The discrepancy with ImmunoRatio™ was most evident 
with a low (Allred score = 0) or high manual Allred score (Allred score = 4 and 
5). The latter could have been due to the underestimation of the LI due to the 
inability of the ImmunoRatio™ software to differentiate cancer nuclei from the 
stromal elements (Figure 22b). Whilst amongst ERα negative cores (Allred 
score = 0) using manual method (n=43), ImmunoRatio™ identified background 
staining, blotching and inflammatory infiltrate staining as false positive in 19 
cores, resulting in an Allred score of 1 (n=5) or 2 (n=14). 
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3.4.2 Ki67 
The median age at breast cancer diagnosis was 65 years (IQR = 21) amongst 
the Ki67 cohort (n = 64). A direct comparison between Ki67 manual and 
ImmunoRatio™ scores were possible as both calculated the proportion of DAB 
stained nuclei in the TMA core. There was a statistically significant correlation 
(Figure 23) between the manual and ImmunoRatio™ Ki67 score (Pearson 
correlation = 0.675; p = 0.000). However, when the Bland-Altman plot (Figure 
24) was used for determining the measure of agreement between the scores, it 
became evident that majority of the values were spread away from zero. This 
indicated that both the manual and ImmunoRatio™ scores produced different 
results for the expression of Ki67. Similarly it can be seen that the manual 
scoring was higher than that of the observed Ki67 expression using 
ImmunoRatio™. The mean difference between the manual and ImmunoRatio™ 
Ki67 score was 17.76 (SD ± 12.64; CI - 7.023 to 42.54). This discrepancy may 
have been due to the inability of the software to differentiate between the 
cancer nuclei and the stromal elements resulting in an underestimation of 
ImmunoRatio™ LI.  
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Figure 24: Measure of agreement between manual and ImmunoRatio™ Ki-67 
scores 
 
Bland-Altman plot showing the manual Ki67 score being significantly higher compared 
to the ImmunoRatio™ Ki67 score. 
Figure 25: Schematic representation of strong counter staining obscuring the 
colour deconvoluted ImmunoRatio™ image 
                                     
               Figure. 25a                                                                    Figure. 25b 
a) The original ERα immunohistochemistry image saved in the JPEG format; b) The 
colour deconvoluted ImmunoRatio™ image. The strong counter staining in this TMA 
core resulted in obscuring the DAB stained nuclear area in the processed image 
leading to lower labelling index.  
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3.5 DISCUSSION  
Hormone receptor status is one of the most important factors which determine 
the choice of adjuvant therapy for patients with breast cancer. Amongst 
hormonal receptors, ERα remains the most reliable predictor for response to 
endocrine therapy (Speirs and Walker, 2007). Evaluation of ERα by IHC 
therefore is standard practice in the management of breast cancer patients. 
There has been a growing interest in the use of a panel of biomarkers for 
prognostic and predictive purposes in breast cancer due to the heterogeneous 
nature of the malignancy. As a proliferative marker, Ki67 gene expression is 
utilised in Oncotype Dx™ and Mammaprint™ assays for determining suitability 
for the choice of adjuvant treatment in breast cancer patients. In clinical trials, 
IHC evaluation of Ki67 expression is used as the assay of choice for 
determining the proliferative nature of the cancer (Dowsett et al., 2011). 
Manual scoring is the gold standard for IHC analysis, but automated image 
analysis systems have shown promising improvement over the last decade 
(Mohammed et al., 2012, Rexhepaj et al., 2008). Centralisation of the services 
and the resulting increased laboratory workload and volume is one of the driving 
forces behind the development of automated image analysis systems. Various 
automated image analysis systems are available commercially, which include 
those that are fully automated (Slidepath Tissue IA System (Mohammed et al., 
2012); Beecher Instruments, TMAx™; (Akbar et al., 2015)) and others which 
are semi-automated (Applied Imaging, Ariol™; Aperio, TMA-Lab II™; Aperio 
IHC Nuclear Version 10 algorithm, Aperio Technologies).  
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The aim was to externally validate ImmunoRatio™ a freely available web based 
fully automated image analysis system (Tuominen et al., 2010) for scoring 
nuclear biomarkers in a cohort of breast cancer patients. The ease of navigation 
and rapid processing of the uploaded images within the ImmunoRatio™ website 
is advantageous. To perform the algorithm, user input is required to select 
nuclei which best match the size of the stained nuclei to be evaluated. However 
the software cannot differentiate cancerous nuclei from those of other cell types. 
There was poor discrimination of nuclei of normal breast epithelial cells and 
inflammatory cell infiltrates surrounding cancer cells.  This is arguably one of 
the biggest challenges faced by automated systems which still cannot 
outperform a trained histopathologist (Gurcan et al., 2009). However 
researchers have recently identified fully automated computer generated 
algorithm to differentiate between cancer and non-cancerous areas in TMA 
cores (Akbar et al., 2015). The authors of the study have also internally 
validated the algorithm using ERα scoring in breast cancer TMAs and have 
shown promising results (Akbar S et al 2015).  
The smallest available nucleus size was selected in all the TMA cores analysed 
in this study. Altering the size of the selected nuclei or other features in the 
advanced mode did not impact on the ImmunoRatio™ ERα or Ki67 score. 
Hence majority of the images (> 90%) were analysed using the basic mode 
platform available in the ImmunoRatio™ website. 
The standardisation of counter staining is very important during IHC image 
evaluation of automated image analysis systems. Though the counter staining 
was relatively homogenous in the ERα cohort, occasionally strong counter 
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staining obscured the area under evaluation by the ImmunoRatio™ software 
(Figure 25a and 25b). ImmunoRatio™ is also susceptible to the known inability 
of the fully automated image analysis systems to differentiate between areas of 
section damage, dye precipitates and out of focus scanning.  
It is well documented within the literature that automated image analysis 
systems perform less reliably when there is a multi-compartmental staining 
pattern (Bolton et al., 2010). The International Ki67 in Breast Cancer Working 
group acknowledge the cytoplasmic staining of Ki67 using various antibodies 
and recommended that only the nuclear staining should be taken in to 
consideration while analysing Ki67 (Dowsett et al., 2011). The background 
cytoplasmic staining obscured and diminished the ability of the ImmunoRatio™ 
software to distinguish true nuclear Ki67 staining. Hence only TMA cores with 
unequivocal nuclear staining and only mild background cytoplasmic staining 
was selected for analysis (Methodology section 3.3.1, Figure 18, Page no. 86). 
In comparison to some of the commercially available fully automated systems 
(Mohammed et al., 2012, Rexhepaj et al., 2008), ImmunoRatio™ does not 
account for the intensity of the nuclear staining. Nuclear intensity is measured 
as a component of analysing ERα using the Allred method, which is considered 
as the current gold standard. However there is some evidence to suggest that 
the presence of 10% ERα positive tumour cells should be the ideal cut-off for 
predicting the response to adjuvant hormonal therapy (Pertschuk et al., 1996). 
This view was further supported by the recommendation of the American 
Society of Clinical Oncology and College of American Pathologists, who 
advised that ERα expression should be reported as the percentage of positive 
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nuclei due to the clinically observed response of some breast cancer with low 
levels of ERα expression (Harvey et al., 1999). Therefore ERα LI as determined 
by ImmunoRatio™ can be applied in a research setting but cannot yet be 
recommended for analysis of individual patients in the context of treatment 
tailoring.  Even though the current standard for determining the Ki67 
proliferative index is similar to that determined using ImmunoRatio™ LI, there 
were significant discrepancies observed between manual and ImmunoRatio™ 
scoring. Hence a fully automated image analysis system should be able to 
differentiate cancer nuclei from stromal elements, account for the background 
cytoplasmic staining and also have options available to select representative 
areas to be scored within the TMA core for it to be reliably used for determining 
Ki67 proliferative index.  
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3.6 CONCLUSION 
The external validation of ImmunoRatio™ showed excellent correlation between 
manual and ImmunoRatio ERα scoring in breast cancer TMAs. However it was 
not possible to validate ImmunoRatio™ for analysing Ki67 in breast cancer due 
to antibody specificity issues and the inability of the software to process multi-
compartmental staining. It is recommended that there should be further 
development of the ImmunoRatio™ software and external validation of it before 
it can be used for the evaluation of Ki67 in breast cancer.  
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CHAPTER 4 
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4 Gene Expression Profiling in 
Matched Male and Female Breast 
Cancer Patients 
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4.1 INTRODUCTION 
It is well established that as with most of the solid tumours, the development 
and progression of breast cancer is a multistep process with genomic alteration 
playing a vital role by affecting gene expression and hence the various 
downstream cellular processes. The heterogeneous nature of FBC is well 
established at genomic level and has been correlated to its prognosis (Sorlie et 
al., 2003, Perou et al., 2000, Hu et al., 2006). Female breast cancer has been 
classified using gene expression profiling in to intrinsic subtypes (Luminal A, 
Luminal B, Her2 positive and Basal-like/triple negative), with unique clinical and 
biological behaviours (Sorlie et al., 2003, Perou et al., 2000, Hu et al., 2006). 
Based on genomic aberrations, FBC has been further classified in to three 
unique genomic subgroups (Fridlyand et al., 2006), which has been externally 
validated (Chin et al., 2006). More recently, using a high resolution array 
comparative genomic hybridisation (aCGH) method, the FBC genomic 
subgroups has been further differentiated into six subgroups (Jonsson et al., 
2010). 
However there is paucity in the knowledge of MBC at transcriptomic level, with 
very few studies exploring its potential. Earlier studies conducted identified 
comparable genetic changes in male and female breast cancer using a 
comparative genomic hybridisation (CGH) method (Tirkkonen et al., 1999, Ojopi 
et al., 2002). A more recent study confirmed these findings and showed 
similarities between male and female breast cancer in the chromosomal gains 
observed at 1q, 8q, 16p and 17q as well as for losses at 8p, 16q, 13q and 11q 
(Rudlowski et al., 2006). Similar findings were observed by Piscuoglio et al with 
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gains of 1q, 8q and 16p and losses of 1p, 16q and 17p in MBC (Piscuoglio et 
al., 2016). 
More recent studies have however made use of the aCGH technology 
(Johansson et al., 2012, Johansson et al., 2011, Tommasi et al., 2010), which 
provides high resolution and better genetic yield compared to the metaphase 
based CGH studies. These high throughput gene expression studies revealed 
significant differences amongst similarities between male and female breast 
cancers with chromosomal gains being more common in MBC compared to 
deletions in FBC (Johansson et al., 2011). Based on these results,  they 
classified MBC into two distinctive groups, male simple and complex 
(Johansson et al., 2011). They identified significant similarities amongst the 
male complex and female complex sub-groups. Conversely, the male simple 
group was unique and was different from all the other 6 established FBC 
subgroups. They also showed that, the male simple group was less aggressive 
and hence associated with a better outcome. The similarities observed between 
male and female breast cancer through CGH studies have suggested that, the 
fundamental genes involved in breast cancer development and evolution may 
be fairly similar (Rudlowski et al., 2006, Tirkkonen et al., 1999).  
However, Callari et al., (2011) showed that there was a substantial difference 
between male and female breast cancer with differentially regulated biological 
process observed on gene ontology (GO) analysis. Particularly interesting was 
the difference noted in the up-regulation of the proteins associated with 
eukaryotic translation (EIF4 and ribosomal proteins) as well as the lack of 
preference for anaerobic metabolism noted in MBC (Callari et al., 2011). 
106 
 
Furthermore, there was down regulation of ERBB2 and growth factor 
associated genes with over expression of BCL2 in MBC cases (Callari et al., 
2011). It has been also shown that up-regulation of EIF4E selectively enhances 
the translation of genes involved in tumourigenesis such as MYC and BCL2 
(Graff et al., 2008). The enhancement of protein synthesis observed on gene 
expression analysis has been linked to the development of MBC through 
increased cell growth, proliferation and activation of the tumour oncogenes. 
Similarly, cluster analysis based on the expression of receptor correlated genes 
(ERBB2, AR and PGR) showed significant differences between male and 
female breast cancers (Callari et al., 2011). The AR correlated genes were 
expressed more in MBC, whereas both ERBB2 and PGR related genes in FBC. 
In comparison to FBC, they noted that there was a 10 fold decreased 
expression of genes correlated with ERBB2 in MBC (Callari et al., 2011). 
Similarly, hierarchical clustering of MBC based on differentially expressed 
genes associated with PGR positive and negative tumours identified from 
internal and publically available FBC data sets showed significant differences 
between male and female breast cancer (Callari et al., 2011). Overall these 
results indicate a diminished role for ERBB2 with AR being the driving gene in 
MBC biology and a possible different role for PGR in MBC compared to FBC. 
Johansson et al., (2012) successfully classified MBC in to two subgroups, 
luminal M1 and M2, based on gene expression profiling. This correlated well 
with that of the male complex and simple subgroups identified respectively 
using genomic aberration study (Johansson et al., 2011). The luminal M1 and 
M2 subgroups were unique and different from that of the already established 
107 
 
FBC molecular subgroups (Giordano et al., 2004). On GO analysis it was 
observed that, the luminal M1 subgroup was associated with up-regulation of 
genes involved in cell cycle, cell migration, cell adhesion and cell division as 
well as HOX genes (Johansson et al., 2012). Conversely, higher expression of 
immune response and ER related genes were observed among the luminal M2 
group (Johansson et al., 2012). The luminal M1 subgroup was the more 
frequent and aggressive phenotype in comparison to the luminal M2, which was 
associated with significant survival advantage.  
More recently candidate driver genes have been identified in MBC (Johansson 
et al., 2013). The study conducted in 53 MBC and 359 FBC tumours identified 
30 candidate driver genes in MBC and 67 in FBC tumours. However there were 
only 2 candidate driver genes that were in common (TAF4 and CD164). 
Whereas the analysis performed only in the MBC data set identified 45 
candidate driver genes. In MBC, amongst the candidate driver genes only 3 
were established cancer genes, MAP2K4, LHP and ZNF217. These findings 
suggests MBC harbour distinct candidate driver genes compared to FBC. 
The current level of evidences published within the literature shows significant 
similarities amongst differences in somatic genetic changes observed in male 
and female breast cancer. Hence the need for further studies to confirm or 
refute the somatic genetic changes observed in MBC.  
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4.2 HYPOTHESIS 
Current level of evidence suggests difference amongst similarities between 
male and female breast cancer. Hence it was hypothesised that, there will be 
significant differences between male and female breast cancer at transcriptomic 
level, leading to changes downstream ultimately resulting in the biological 
differences between male and female breast cancer. 
4.2.1 Aim  
1. Identify differentially expressed genes of statistical significance in 
matched male and female breast cancer through gene expression 
profiling. 
2. Amongst differentially expressed genes, identify the protein expression of 
a gene or a group of genes with clinical significance and evaluate its 
prognostic significance in MBC cohort using IHC.  
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4.3 METHODOLOGY 
4.3.1 Gene Expression Profiling 
Matched male (n=15) and female (n=10) breast cancer patients were identified 
for gene expression profiling. The patients were identified from an existing 
database maintained at Pathology Department, Leeds Institute of Molecular 
Medicine, University of Leeds. The groups were matched for known prognostic 
pathological variables (type of cancer, hormonal receptors and lymph nodal 
status) as well as for the treatments received (surgical and adjuvant). Only 
invasive ductal cancers which were G1/2 with no lymph nodal involvement or 
N1 disease (1 to 3 involved nodes) were selected.  
Even though macro dissection was not performed, H&E staining of the sections 
were performed to ensure that more than 80% of the FFPE sections contain 
breast cancer. The selected FFPE block was sectioned at 10 µm thickness 
(performed by Ms. Jennifer Pollard) and a minimum of four untreated sections 
were sent to ALMAC diagnostics™ in RNase-free-tube. Samples were 
randomised and re-named to prevent order bias and batching effect by ALMAC 
diagnostics™ (ALMAC diagnostics, Craigavon, United Kingdom). The gene 
expression profile experiment was undertaken by ALMAC diagnostics™.  A 
summary of the methodology for gene expression profiling as disclosed by 
ALMAC diagnostics™ is detailed below. 
4.3.1.1 RNA isolation  
“All FFPE tissues (pre-cut section “curls” in RNase-free tubes) were first de-
paraffinized with a xylene-based extraction followed by ethanol dehydration. 
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Tissue samples were then disrupted during an overnight incubation with a 
Proteinase K lysis buffer. Nucleic acids were bound to a glass fiber filter in the 
presence of a chaotropic salt under conditions that were optimized specifically 
for RNA recovery. Bound RNA was subjected to a series of wash steps to 
remove contaminating cellular components, and any residual DNA was digested 
by incubation with DNase. A second round of Proteinase K digestion followed 
by further wash steps was done to improve the final purity of the RNA, which 
was then eluted from the glass fibers in a small volume of low-salt elution buffer. 
The RNA samples were examined for concentration and purity using a 
spectrophotometer and the standards used are detailed in appendices 3 (Page 
no. 180)”. 
4.3.1.2 Amplification of total RNA 
“Total RNA was amplified using the NuGEN™ WT-Ovation™ FFPE RNA 
Amplification System. First-strand synthesis of cDNA was performed using a 
unique first-strand DNA/RNA chimeric primer mix, resulting in cDNA/mRNA 
hybrid molecules. Following fragmentation of the mRNA component of the 
cDNA/mRNA molecules, second-strand synthesis was performed and double-
stranded cDNA was formed with a unique DNA/RNA hetero-duplex at one end. 
In the final amplification step, RNA within the hetero-duplex was degraded using 
RNaseH, and replication of the resultant single-stranded cDNA was achieved 
through DNA/RNA chimeric primer binding and DNA polymerase enzymatic 
activity. The amplified single-stranded cDNA was purified for accurate 
quantitation of the cDNA and to ensure optimal performance during the 
fragmentation and labelling process. The single stranded cDNA was assessed 
using spectrophotometric methods in combination with the Agilent Bioanalyzer. 
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The details of the quality control performed in the single stranded cDNA are 
described in appendices 4 (Page no. 181)”. 
4.3.1.3 cDNA processing  
“The appropriate amount of amplified single-stranded cDNA was fragmented 
and labelled using the FL-Ovation™ cDNA Biotin Module V2. The enzymatically 
and chemically fragmented product (50-100 nt) was labelled via the attachment 
of biotinylated nucleotides onto the 3'-end of the fragmented cDNA. The 
resultant fragmented and labelled cDNA was added to the hybridization cocktail 
in accordance with the NuGEN™ guidelines for hybridization onto Affymetrix 
GeneChip® arrays. Following hybridization for 16-18 hours at 45°C in an 
Affymetrix GeneChip® Hybridization Oven 640, the array was washed and 
stained on the GeneChip® Fluidics Station 450 using the appropriate fluidics 
script, before being inserted into the Affymetrix autoloader carousel and 
scanned using the GeneChip® Scanner 3000”. The array data generated was 
subjected to assessment of GeneChip quality control and expression data 
integrity. The details of the quality control and data integrity analysis performed 
are described in appendices 5 (Page no. 182-186). Three MBC samples which 
failed quality control and data integrity analysis were removed before continuing 
the analysis”.  
4.3.1.4 Data summarisation and normalisation  
“The scanned Almac Breast DSA™ microarray image data was translated into 
signal intensities using Robust Multichip Algorithm (RMA) to determine the 
transcript abundance. The RMA using Affymetrix' Expression Console version 
1.1, was applied to the raw data in order to generate the processed data. The 
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first step was to correct the probe signals for background. The background 
correction component of RMA assumes the observed signal is a combination of 
an exponentially distributed true signal and a normally distributed noise 
component. Once the background subtraction has been performed, all arrays 
are normalised using a quantile normalisation procedure. It was assumed that 
the distribution of probe abundances is nearly the same in all samples for 
quantile normalisation procedure. Finally a median polish was used to calculate 
a summary value for each probe set”.  
4.3.1.5 Differential gene selection 
The ALMAC diagnostics™ used an in-house method to select differentially 
expressed probe sets using background, variance and fold change filters using 
FeatureSelection_Workflow version 102. All probe sets (60,856) on the Almac 
Breast DSA™ array was subjected to general filtering with background and 
variance filtering. Any probe set with an expression on the background level 
(Background p-value = 0.3) was removed. Similarly, any probe set with a 
variance below the mean global variance was removed in an intensity 
dependent manner (α-value = 0.9). The group and statistical filtering was 
performed in 14,959 probe sets that passed the general filtering criteria. The 
data was then filtered using an advanced fold change filter to identify those 
probe sets that are differentially expressed. The student’s t-test was performed 
on the probe sets passing general and fold change filters to determine the 
statistical significance after multiple test correction (pFDR).  
The preliminary findings of the GEP experiment including bioinformatics data 
and functional enrichment analysis was provided by ALMAC diagnostics™. 
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Subsequent bioinformatics data mining, analysis, interpretation of the results 
and drawing inference for further validation was undertaken through guidance 
from Dr. Alastair Droop, Bioinformatics research fellow at University of Leeds.  
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4.3.2 Western Blot 
The experiment was performed under the guidance of Dr E T Verghese (PhD 
Research Fellow, University of Leeds) to determine the specificity of the 
Fibronectin antibody used for immunohistochemical analysis. 
4.3.2.1 Reagents used for Western Blot 
1. 4 x NuPage® Lithium Docedyl Sulphate (LDS) Sample Buffer (pH 8.5) 
The stock was obtained from Life Technologies, Carlsbad, USA. The 
components of NuPage® LDS sample buffer (500 ml) is as follows,  
Glycerol  10% (v/v) 
Tris base (pH 8)  424 mM 
Tris-hydrochloric acid 564 mM 
LDS  2% (w/v) 
Ethylene di-amine tetra-acetic acid (EDTA) 0.5 mM 
Serva blue G250 1 mM 
Phenol red  0.7 mM 
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2. 20 x NuPAGE® MOPS Sodium Dodecyl Sulphate (SDS) Running Buffer (pH 
7.2) 
The stock was obtained from Life Technologies Carlsbad, USA. The 
components of the 20 x NuPAGE® MOPS SDS Running Buffer (500 ml) is as 
follows,  
3-(N-morpholino) propane sulphuric acid (MOPS) 1.0 M 
Tris Base (pH 8) 1.0 M 
Sodium dodecyl sulphate (SDS) 70 mM 
EDTA (pH 8) 20 mM 
 
3. 20 x NuPAGE® MOPS SDS Transfer Buffer (pH 7.2) 
The stock was obtained from Life Technologies Carlsbad, USA. The 
components of the 20 x NuPAGE® MOPS SDS Transfer Buffer (500 ml) is as 
follows, 
Bicine 500 mM 
Bis-Tris  500 mM 
EDTA (pH 8) 20 mM 
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4. β – Mercaptoethanol  
Obtained from Sigma Aldrich, St. Louis, USA (Catalogue no: M3148). 
5. Precast NuPAGE® Novex® 4-12% Bis-Tris Gel (0.1mm, 10 wells) 
Obtained from Invitrogen, Carlsbad, USA (Catalogue no. NP0321) 
6. Amersham Hybond - P Polyvinylidene Difluoride (PVDF) membrane  
Obtained from GE Healthcare, Little Chalfont, UK (Catalogue no. RPN2020F) 
7. Tween – 20 
Obtained from Fisher Scientific, Waltham, USA (Catalogue no: PBP337-100). 
8. Tris-Buffered Saline Tween (TBST) 
The components of TBST are Tris-Buffered Saline (TBS) (pH 7.4) and Tween 
20. 1 x TBS (1 litre) was made by mixing 60 ml of stock solution of 2.5 M NaCl 
and 20 ml of 1 M Tris-Hydrochloric acid (Tris-HCl) (pH 7.4) in deionised water.  
Sodium chloride  0.15 M 
Tris-HCl 0.02 M 
Tween -20  0.1% (v/v) 
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9. Polyclonal Swine Anti Rabbit horse radish peroxidase (HRP) conjugated 
secondary antibody 
Obtained from Dako, Santa Clara, USA (Catalogue no: P0217). 
10. Protein Molecular Weight Markers  
 SeeBlue® Plus2 Pre-stained Protein Standard was used. 500 µl stock was 
obtained from ThermoFisher Scientific, Paisley, UK (Catalogue no. LC5925). 
11. SuperSignal® West Femto Chemiluminescent Substrate  
Obtained from Thermo Scientific, Waltham, USA (Catalogue no: 34095) 
4.3.2.2 Gel Electrophoresis of Proteins  
1. Sample preparation 
Standardised protein was added to 1 x LDS sample buffer (pH 8.5) containing 
5% (v/v) of β-mercaptoethanol in a 0.5 ml Eppendorf tubes to make a total 
volume of 20µl. The Eppendorf tubes were then closed, the cap pierced using a 
21 gauge needle, spun and then placed in a hot plate at 1050 for 5 minutes. The 
tubes were then transferred to ice for 5 minutes. The tubes were centrifuged for 
30 seconds at 8,000g and then gently re-suspended and placed on the ice.  
2. Gel preparation  
The Precast NuPAGE® Novex® 4-12% Bis-Tris Gel was carefully removed from 
package and gently rinsed with tap water. The 1 x NuPAGE® MOPS SDS 
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running buffer was made by mixing 475 ml of deionised water and 25 ml of 20 x 
NuPAGE® MOPS SDS running buffer. The running buffer is added to the top of 
the gel until it fills quarter of the tank. Twenty microgram of sample and 5 µl 
SeeBlue® plus2 marker was added to the lanes.  Electrophoresis was then 
performed in Xcell SureLock™ Mini-Cell system (life Technologies, Model no: 
EI0001) at a constant current of 180V for 1 to 1.5 hours.  
3. Transfer of proteins 
Amersham Hybond-P Polyvinylidene difluoride (PVDF) membrane was used for 
transferring the proteins separated through gel electrophoresis. The 1 x 
NuPAGE® MOPS SDS transfer buffer was used to prime the filter paper and 
sponges used for the protein transfer. The membrane itself is activated by 
soaking in neat methanol for 30 second, washed in deionised water for 10 
minutes with constant agitation on a shaker and finally soaked in the transfer 
buffer. The pre-cast gel was removed before loading into the transfer module 
with the membrane in place over the gel ensuring that there are no air bubbles. 
The transfer module is then filled with the transfer buffer and run at a constant 
current of 30 V for 1.5 hours.  
4. Immunoblotting of proteins 
The PVDF membrane with the transferred proteins was blocked in 20 ml of 
blocking buffer for 1.5 hours at room temperature. The blocking buffer consists 
of Tris buffered saline with tween (TBST) and 5% (w/v) of Marvel skimmed milk. 
The membrane was then washed 3 x 10 min with TBST with gentle agitation on 
spiramix. The membrane was then transferred to 5% (w/v) skimmed dried milk 
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(Marvel) in TBST containing primary antibody, anti-fibronectin 1 (anti-FN1) in 
1:250 concentration. The membrane was then allowed to incubate with the 
primary antibody overnight at 40C on a roller. The membrane was then washed 
3 times in TBST for 10 minutes each. The membrane was then incubated in 5% 
(w/v) skimmed dried milk (Marvel) in TBST with secondary antibody (Polyclonal 
swine anti-rabbit HRP conjugated) at 1: 5000 dilutions for one hour at room 
temperature. Subsequently the membrane was again washed 3 times in TBST 
for 10 minutes each. During optimisation of secondary antibody, samples were 
tested by incubating without primary antibody to ensure there aren’t any false 
positive results. The membrane was then incubated with 200µl of SuperSignal® 
West Femto Chemiluminescent substrate for 5 minutes to facilitate visualisation 
of the antibody. The membrane was covered in a cling film ensuring that there 
are no air bubbles and visualised using ChemiDoc® MP imaging system (Bio-
Rad, model no.170-8280), with exposure time varying depending on the signal 
intensity. The control ladder used was Precision Plus Protein™ Dual Colour 
Standards (BioRad, Cat no. 161-0374). 
4.3.3 Immunohistochemistry 
IHC analysis for Fibronectin was performed in MBC TMAs 1 to 6, TMA 8 and 
was not performed in MBC TMA 7 due to core exhaustion. A rabbit polyclonal 
anti-fibronectin 1 (anti-FN1) antibody (Prestige Antibodies® Powered by Atlas 
Antibodies, Product no:  HPA027066), which was validated in Human Protein 
Atlas project was used in this cohort.  
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The IHC was performed with EnVision method as described earlier (Chapter 2, 
Methodology Section 2.3.3, Page no. 33-34).  The main differences was that  
instead of using PBS, PBS with 0.2% Tween (PBST) was used for washing the 
slides and the slide racks were not passed through copper sulphate prior to 
counter staining with Mayer’s haematoxylin. The anti-FN1 antibody was used at 
1:50 concentration in the MBC TMAs and overnight incubation was done in a 
humidified chamber at 40C. The anti-rabbit secondary antibody conjugated with 
HRP was used (DAKO® –Envision Kit) for visualisation of the antigen-antibody 
reaction.  In each batch, a breast cancer control TMA was used for positive 
control and negative control was run by incubating with PBST instead of primary 
antibody.   
The anti-FN1 antibody was optimised in male and female breast cancer full 
slide sections to confirm the location and intensity of the staining. Subsequently, 
a control FBC TMA was used to confirm the ideal concentration of the antibody 
in TMAs.  
The manual IHC scoring was performed after scanning the slides at 20x 
magnification (ScanScope XT, Aperio) using the ImageScope™ software 
(Aperio). A random selection of TMA cores (n = 100) were also scored by an 
independent researcher (Dr E T Verghese, PhD Research Fellow, University of 
Leeds) to ensure minimal inter-observer variability. 
4.3.4 Statistical analysis 
The clinical and pathological variables, like age at diagnosis, tumour size, grade 
and nodal status were available for analysis in the MBC TMA cohort. The main 
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outcome variable was overall survival (OS). The correlation between fibronectin 
expression and various clinical and pathological variables were calculated using 
Spearman’s correlation coefficient. The measure of agreement was calculated 
using the Κ statistics. The strength of association between clinico-pathological 
variables and fibronectin with that OS was ascertained using Cox logistic 
regression analysis.  The prognostic variables that were significant on univariate 
analysis were then entered in to a multivariate analysis model to identify 
independent predictors for OS at 5 year. The survival analysis was performed 
using the Cox proportional hazard model. The survival curves were plotted 
using Kaplan-Meier method and compared using the Log rank test. The data 
was analysed using SPSS version 19 software and a P value of ≤ 0.05 was 
considered as statistically significant.  
4.3.4.1 Bioinformatics  
The ALMAC Diagnostics Breast DSA™ research tool consisting of 60, 856 
probe sets were used in the gene expression profiling analysis. The Robust 
Multichip Algorithm (RMA) using Affymetrix™ Expression console version 1.1 
was applied to the raw data in order to generate the processed data. 
Differentially expressed probe sets were identified using background, variance 
and fold change filters with FeatureSelection_Workshlow version 102. Further 
details of the initial bioinformatics analysis performed by ALMAC Diagnostics™ 
are detailed in Appendix 6 (Page no. 187).  
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4.4 RESULTS  
Bioinformatics analysis (performed by ALMAC Diagnostics™) was undertaken 
to identify probe sets that were differentially expressed. The general filtering 
was carried out using background expression and variance filters to identify a 
list of 14,949 probe sets. The criteria used was to remove any probe set with an 
expression on the background level (p = 0.3). Similarly, any probe set with a 
variance below the mean global variance was removed in an intensity 
dependent manner (α-value = 0.9). The data was then subjected to advanced 
fold change filtering based on the intensity and variation of probe sets between 
the groups. Student’s t-test was performed to determine differentially expressed 
probe sets and false discovery rate (pFDR) was calculated to account for 
multiple test correction. There were 735 differentially expressed genes using the 
less stringent criteria (Significance level for log fold change = 0.05) and 117 
genes were differentially expressed using the stringent criteria (Significance 
level for log fold change = 0.01). Hierarchical agglomerative clustering was 
undertaken amongst differentially expressed genes, using both less stringent 
(Figure 26) and stringent criteria (Figure 27). The agglomerative clustering 
starts with each sample/gene as a separate cluster and merge them into 
successive larger clusters. The analysis was performed in Partek GS v 6.5. 
Functional enrichment analysis of differentially expressed genes identified with 
the less stringent criteria (n=735) was undertaken using Ingenuity Pathway 
Analysis (IPA v9.0 build 116623, Ingenuity® Systems, content version 3211) 
and Gene Ontology (GO) analysis using Functional Enrichment Tool (FET 
version 1.0).  
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Figure 26: Heat map showing hierarchical clustering using less stringent criteria 
(p ≤ 0.05) 
 
Hierarchical agglomerative clustering showing differentially expressed genes in the 
male and female breast cancer samples using less stringent criteria (p ≤ 0.05). Rows: 
individual genes; Columns: individual tissue samples. Pseudo-colours indicate 
transcript level below, equal to or above the mean (green, black and red respectively). 
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Figure 27: Heat map showing hierarchical clustering using stringent criteria (p ≤ 
0.01) 
 
 
Hierarchical agglomerative clustering showing differentially expressed genes in the 
male and female breast cancer samples using stringent criteria (p ≤ 0.01). Rows: 
individual genes; Columns: individual tissue samples. Pseudo-colours indicate 
transcript level below, equal to or above the mean (green, black and red respectively). 
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The significance of the association between differentially expressed genes to 
the total number of genes in a canonical pathway/GO term was expressed as a 
ratio and Fisher’s exact test was performed to establish statistical significance. 
Benjamini & Hochberg adjusted p-value was calculated to account for multiple 
testing and represented as pFDR. The top 10 enriched canonical pathways and 
biological processes are represented respectively in Table 10 and 11.  
 
Table 10: Top 10 enriched canonical pathways 
No Ingenuity Canonical Pathways  Ratio p-value p-value (FDR)  
1 Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
15/147 0.0000 0.0115 
2 EIF2 Signalling 11/101 0.0001 0.0162 
3 Actin Cytoskeleton Signalling 16/238 0.0007 0.0589 
4 Glioma Invasiveness Signalling 8/60 0.0008 0.0589 
5 Leukocyte Extravasation Signalling 15/199 0.0013 0.0676 
6 Intrinsic Prothrombin Activation Pathway 5/34 0.0014 0.0676 
7 ILK Signalling 14/193 0.0020 0.0851 
8 Glucocorticoid Receptor Signalling 18/295 0.0026 0.0912 
9 VEGF Signalling 9/99 0.0028 0.0912 
10 Rac Signalling 10/123 0.0035 0.1033 
 
 
Table 11: Top 10 enriched biological processes  
No GO Biological Process  Ratio p-value p-value 
(FDR)  
1 GO:0007155 cell adhesion 68/708 0.0000 0.0000 
2 GO:0022610 biological adhesion 68/709 0.0000 0.0000 
3 GO:0031589 cell-substrate adhesion 19/137 0.0000 0.0002 
4 GO:0006928 cellular component movement 38/458 0.0000 0.0003 
5 GO:0030199 collagen fibril organization 8/26 0.0000 0.0009 
6 GO:0009653 anatomical structure morphogenesis 63/1023 0.0000 0.0016 
7 GO:0048519 negative regulation of biological 
process 
93/1754 0.0000 0.0029 
8 GO:0048856 anatomical structure development 113/2253 0.0000 0.0029 
9 GO:0007160 cell-matrix adhesion 14/105 0.0000 0.0040 
10 GO:0048523 negative regulation of cellular process 86/1610 0.0000 0.0040 
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The data and results as detailed above provided by Almac Diagnostics™ were 
scrutinised and was subjected to further data mining. Since the cohort 
contained matched male and female breast cancer patients, there was selection 
and analytical bias originating from differentially expressed sex linked genes. 
Hence sex linked genes / probe sets were excluded (n = 79) and analysis was 
repeated in the remaining 656 probe sets. The hierarchical clustering performed 
using the new gene set generated a more representative cluster of differentially 
expressed genes (Figure 28).  The majority of genes were up-regulated (n = 
487) and rest were down-regulated (n = 169).  
The subsequent data mining concentrated on identifying either a cluster or a 
group of genes with a role in the natural history of breast cancer. The data was 
initially analysed using the group of genes represented in 9 major clusters or 
within its sub-clusters (Figure 29). The genes in each cluster were entered into 
Oncomine™ and/or ToppGene™ database to extract biological insights into the 
data. In addition to this, the top 10 up and down regulated genes encoding for 
proteins were individually analysed (Table 12 and 13). The role of each 
individual gene in cancer and in particular breast cancer was extracted from 
publically available data sets and literature. The information was mostly 
gathered from various resources available within the National Center for 
Biotechnology Information (NCBI) website. In the NCBI site the “Gene 
Expression Omnibus” (GEO) and “Gene” depositories were mainly used for 
data mining. The bibliography there in was reviewed to identify published 
evidence supporting the role of individual genes in breast cancer.  
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Figure 28: Hierarchical agglomerative clustering of less stringent genes after 
excluding sex linked genes 
Female breast cancer cases Male breast cancer cases
 
 
Hierarchical agglomerative clustering showing non-sex linked differentially expressed 
genes with less stringent criteria (p ≤ 0.05) in the matched male and female breast 
cancer groups. Rows: individual genes; Columns: individual tissue samples. Pseudo-
colours indicate transcript level below, equal to or above the mean (green, black and 
red respectively).  
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Figure 29: Representation of the 9 clusters selected from the heat map and 
representative genes used for data mining. 
 
 
The red dotted line represent the level at which 9 clusters was selected. Different 
colour was assigned to each cluster of genes.   
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Table 12: The top 10 up-regulated non-sex linked genes in matched male and 
female breast cancer samples  
Gene Symbol Gene Description 
Chromosomal 
Location 
Fold-
Change 
(A vs. B)* 
p value pFDR** 
GJA1 Gap junction protein, alpha 1 6p11.1 8.26212 0.000436 0.000045743 
STC2 Stanniocalcin 2 5p11 7.61776 0.006737 0.00010712 
SERPINA6 Serpin peptidase inhibitor 14p11.1 6.67724 0.001699 0.000081345 
PI15 Peptidase inhibitor 15  8p11.1 5.96069 0.012226 0.00012912 
SULF1 Sulfatase 1 8p11.1 5.30301 0.000853 0.00006264 
FHL2 Four and a half LIM domains 2 2p11.1 4.89209 0.000652 0.000056279 
NPNT Nephronectin 4p11 4.84637 0.015899 0.00014557 
COL1A1 Collagen, type I, alpha 1  17p11.1 4.70691 0.008838 0.00011447 
MMP11 Matrix metallopeptidase 11 (stromelysin 3) 22p11.1 4.62931 0.006139 0.00010772 
FN1 Fibronectin 1  2p11.1 4.33815 0.001337 0.00007548 
 
*“A” represent male samples and “B” represent female breast cancer samples. **pFDR 
(Positive false discovery rate) represent the significance after correction for multiple 
testing. 
 
Table 13: The top 10 down-regulated genes amongst non-sex linked genes in 
matched male and female breast cancer samples  
Gene Symbol Gene Description 
Chromosomal 
Location 
Fold-
Change 
(A vs. B)* 
p value pFDR** 
ERBB4 v-erb-a erythroblastic leukaemia viral 
oncogene homolog 4 
2p11.1 -4.47078 0.001486 0.000076079 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial) 
1p11.1 -3.09543 0.054133 0.00032524 
ZC3H7B Zinc finger CCCH-type containing 7B 22p11.1 -2.81424 0.002774 0.000086649 
IGJ Immunoglobulin J polypeptide 4p11 -2.7442 0.033072 0.00021324 
TFAP2B Transcription factor AP-2 beta 6p11.1 -2.74218 0.033909 0.00021769 
PBX1 Pre-B-cell leukaemia homeobox 1 1p11.1 -2.68953 0.024997 0.00017727 
KCNC3 Potassium voltage-gated channel 19p11 -2.58495 0.021384 0.00016349 
SLC20A2 Solute carrier family 20 (phosphate 
transporter) 
8p11.1 -2.55447 0.049414 0.0002981 
ACACB Acetyl-CoA carboxylase beta  12p11.1 -2.54331 0.011321 0.00012559 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 11p11.11 -2.43954 0.037239 0.00023361 
 
*“A” represent male samples and “B” represent female breast cancer samples. **pFDR 
(Positive false discovery rate) represent the significance after correction for multiple 
testing. 
 
The data mining as detailed above showed an emerging common theme of 
extracellular matrix (ECM) remodelling amongst up-regulated genes. This 
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indeed was reflected in the Gene Ontology results showing up-regulation of 
biological processes involved in ECM remodelling (Table11, Page no. 125). The 
literature was reviewed to identify genes that were shown to be differentially 
expressed in breast cancer stroma compared to normal breast. The literature 
review was limited to FBC due to the lack of published comparative studies in 
MBC. The following studies with publically available data set of genes were 
identified (Ma et al., 2009, Bergamaschi et al., 2008, Karnoub et al., 2007, Finak 
et al., 2008). The differentially expressed gene list (non-sex linked genes) from 
this study was compared with that of the exhaustive gene list extracted from 
public repositories. This enabled to generate a list of common differentially 
expressed genes (Table 14) 
Table 14: Differentially expressed stromal associated genes in this study and in 
other publically available data sets 
Study details  Differentially expressed genes  
Ma et al (2009)  
[>3 fold differential 
expression in IDC stoma 
compared to normal breast 
stroma] 
ANTXR1, ASPN, CACNG4, CD276, CFL1, COL10A1, COL11A1, COL12A1, 
CTHRC1, EIF5, ENTPD7, EPS8, FN1, FNDC1, GLUL, GREM1, INHBA, 
ITGA6, ITGBL1, MFAP2, MMP11, MVP, PXDN, RAB31, SPARC, SULF1, 
SYNPO2L, TUBA1C 
Ma et al (2009) 
[> 3 fold differential 
expression in DCIS stoma 
compared  to normal breast 
stroma] 
ASPN, COL10A1, COL11A1, COL12A1, 
COL8A1,CTHRC1,FN1,FNDC1,GJB2,GREM1,IGJ,INHBA, SULF1 
Finak et al (2008) C1orf31, CAPS, CXCL14, GK, ITGB8, ITGBL1, MYB, SPP1 
Bermaschi et al (2008) 
CD44, CERCAM, COL12A1, COL1A1, COL11, COL3A1, COL4A5, COL5A3, 
COL6A1, COL6A3, FBN1, HTRA3, ITGA6, ITGB3BP, ITGB5, ITGB8, ITGBL1, 
LAMC1, MMP11, MMP13, MMP2, PI15, SERPINA1, SERPINA3, SERPINA6, 
SMOC1, SPARC, TNC 
Karnoub et al (2007) 
CERCAM, COL10A1, COL11A1, COL8A1, CRYAB, CTHRC1, EMP1, FN1, 
GREM1, ITGBL1, MMP11, MSR1, RUNX2, SPP1, SULF1 
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The differential expression of genes identified in this cohort was from matched 
male and female breast cancer samples. Hence it is possible that, the identified 
genes may not be truly differentially expressed in MBC. The differential 
expression observed may be due to either a slight increase (amongst up-
regulated genes) or decrease (amongst down-regulated genes) in the mean 
expression level of that particular gene in all the MBC samples compared to that 
in all of the FBC samples.  
Hence in order to identify genes that are truly differentially expressed between 
MBC and FBC, comparison with publically available data sets were undertaken. 
The differentially expressed genes were individually evaluated in Oncomine™ 
website to determine their expression in FBC compared to that in the normal 
breast tissue. The results showed that 134 out of 487 genes were up-regulated 
in FBC compared to normal breast tissue (Table 15). Similarly 39 out of 169 
genes were down-regulated in FBC compared to normal breast tissue (Table 
15). The genes thus identified (134 up-regulated and 39 down-regulated) were 
compared with genes that were known to have functional role (publically 
available repositories) in ECM remodelling or associated with breast cancer 
stroma. Amongst the up-regulated genes, 15 genes were involved in ECM 
remodelling (Table 16). However none of the down-regulated genes were 
related to ECM remodelling.  
Each of these genes, its role (prognostic or predictive) in breast cancer and its 
relevance in ECM remodelling was explored in the literature. The protein by 
product of these genes and its expression in the breast cancer was analysed.  
Amongst the genes identified, it was decided to validate the protein expression  
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Table 15: Common differentially expressed genes identified in this cohort and in 
the FBC vs. Normal breast analysis of the publically available data sets (Collated 
from the Oncomine™ website)  
Down-regulated genes Up-regulated genes 
HMGCS2 PTPRD MVP FN1 CTHRC1 
IGJ FAM36A MICAL2 SLC39A11 SIAH2 
TFAP2B ANTXR1 SORD RASAL2 VCAN 
ACACB C1orf31 UBE2N ARFIP2 COL11A1 
TFAP2B PTK7 VDR COL10A1 EDIL3 
EDNRB CTNNB1 TGFB3 COL8A1 AGR3 
FBXO2 SYNCRIP MICB INHBA ASPN 
FRMD4A NAV1 MICB --- /// MFAP2 MUC1 
HNRNPA0 EIF2AK1 MSR1 GJB2 CNTNAP2 
N4BP2L2 PIP5K1A GPX8 PXDN CDH11 
ATP5J2 TUBA1C NUDT3 MUC1 COL12A1 
PDHA1 SNX14 PALLD C1QTNF3 MMP13 
BTNL9 HTATSF1 SKIL COL12A1 SERPINA1 
GMPR2 CELF1 LASS2 PLAU MMP11 
HSPA1A /// HSPA1B KIAA2026 SMAD2 SPOCK1 COL1A1 
DDX17 IL1B RUFY1 COL3A1 NPNT 
MAML3 VEZF1 TANC1 INHBA SULF1 
LIMCH1 MIA3 GIPC1 POSTN   
HNRNPA0 TGFB3 TNFAIP6 RAB31   
PIK3R1 S100A13 PDXDC1 CD276   
HSPD1 GMFB FN1 SLITRK6   
SAP18 RNF144B HNRNPUL2 RAB31   
MAT2A IPPK GPSM2 ITGB8   
UBA7 ACTR2 ETNK1 FBN1   
DTWD1 GK PIGX COL1A2   
PILRB PPPDE1 DYNLT3 COL12A1   
STAT5B FN1 FAM36A SULF1   
PPP3R1 RUNX2 TCF12 GAS7   
EIF3CL /// EIF3C TBCK MLLT4 VCAN   
RPL28 ITPK1 PXDN MFHAS1   
NSMCE4A FARP1 SPP1 ENTPD7   
C15orf52 PREPL CERCAM MFAP5   
HNRNPF SH3RF1 HTRA3 COL3A1   
EIF3F TAX1BP3 FNDC1 LUM   
PPP3R1 C18orf1 MYO6 VAV3   
HNRNPAB STK3 GREM1 COL6A3   
N4BP2L2 POSTN MS4A7 CD109   
TRIM28 ZNF207 PTPLB CACNG4   
IRX2 PXDN CDH11 RAB31   
1% 5% 10% 
      
The cell colour is determined by the best gene rank percentile as given in the 
Oncomine™ website. 
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of Fibronectin gene due to its role in ECM. The role of Fibronectin in MBC was 
then evaluated by determining its expression in TMA’s constructed from FFPE 
tissue blocks. 
Table 16: Genes involved in ECM remodelling  
Gene symbol Gene name 
FN1 Fibronectin 1 
COL12A1 Collagen, Type XII, alpha 1 
COL1A1 Collagen, Type I, alpha 1 
COL1A2 Collagen, Type I, alpha 2 
COL3A1 Collagen, Type III, alpha 1 
COL6A3 Collagen, Type VI, alpha 3 
COL10A1 Collagen, Type X, alpha 1 
COL11A1 Collagen, Type XI, alpha 1 
COL8A1 Collagen, Type VIII, alpha 1 
SPARC Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) 
FBN1 Fibrillin 1 
ITGB8 Integrin beta8 
MMP11 Matrix Metallopeptidase 11(Stromelysin 3) 
MMP13 Matrix Metallopeptidase 13 
SERPINA1  Serpin Peptidase Inhibitor (alpha-1 antitrypsin) 
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4.4.1 Immunohistochemistry Evaluation of Fibronectin 
Expression 
The IHC analysis was performed in MBC TMA’s and details of the TMA’s used 
are described in Chapter 2 (Methodology section 2.3.2, Page no. 29-31). The 
only difference being the exclusion of TMA 7 (Canadian group) due to core 
exhaustion. Therefore, the descriptive statistics, measure of association and 
correlation analysis with known prognostic markers were performed in 208 
patients. Whereas, the 5 year survival analysis was performed in 199 patients in 
whom the follow-up data was complete. The clinical and salient pathological 
characteristics of the cohort are as described earlier (Chapter 2, Result section 
2.4, Page no. 41-43).  
The literature was reviewed to establish various antibodies and scoring 
methods used for IHC analysis of FN in FFPE tissue (Tavakoli et al., 2011, 
Sudo et al., 2013, Swiatoniowski et al., 2005, Ioachim et al., 2002). In addition 
to this The Human Protein Atlas™ website was searched to identify other 
validated antibodies. After careful consideration, a rabbit polyclonal antibody 
against FN was selected for IHC evaluation in the MBC cohort (Product No: 
HPA 027066, Atlas Antibodies, SIGMA Life science, St. Louis, USA).  
Even though the FN antibody has been independently validated, its specificity 
for FN was determined using Western Blot method. The specificity of the 
antibody to bind with FN was determined in transformed immortalised 
fibroblasts (Verghese et al., 2011), MCF-7 and MDA-231 cell lines using 
Western Blot (Figure 30a). The results showed a band corresponding to the 
molecular weight of Fibronectin (440kDa) in the fibroblast cell line. Moreover 
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there was no reactivity seen with MCF-7 or MDA-231 cell lines. This finding 
supported the fact that, FN is not routinely expressed by the breast cancer 
epithelial cells (Taylor-Papadimitriou et al., 1981, Gould et al., 1990, Friedman 
et al., 1984).   
The antibody optimisation was performed initially in full section of female normal 
and breast cancer tissue prior to testing in the control TMA. The antibody 
produced optimal staining at 1:50 concentration using the envision method. The 
FN expression in the breast cancer stroma was only determined. The intensity 
of the FN immunoreactivity was determined and graded as negative, mild, 
moderate and strong. The FN immunoreactivity was specific to the stroma but 
occasional cancer epithelial cell staining was observed (Figure30 b-d).  
The FN scoring was performed by two investigators (in 1/3rd of the cases) to 
determine the reproducibility of the scoring method (Dr S Sundara Rajan and Dr 
E T Verghese). The statistical analysis showed good agreement between the 
investigators (Table 17) (κ = 0.68). It was evident that most of the discrepancies 
were between mild to moderate and moderate to strong scoring grades.  
Table 17: Representation of fibronectin immunohistochemistry scoring by two 
independent investigators 
   Investigator 1 
  Fibronectin 
Scoring  
Negative  Mild  Moderate Strong  Total 
In
vestig
ato
r 2 
Negative 3 0 0 0 3 
Mild 1 23 1 0 25 
Moderate 0 5 15 0 20 
Strong  0 0 6 18 24 
Total 4 28 22 18 72 
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Figure 30: Specificity of anti-FN antibody & fibronectin expression in MBC TMA 
cores 
(a) Western blot showing specificity of anti-FN antibody (HPA 027066). A single band 
within 10% of predicted molecular weight of FN (440 kDa) was observed in transformed 
fibroblasts and no bands were identified in epithelial cell lines (MCF-7 and MDA-231). 
GAPDH was used as the loading control. Mild (b) Moderate (c) and Strong (d) stromal 
staining observed with anti-Fibronectin antibody in the male breast cancer TMA’s.  
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There was a clear distinction between those scored as negative or mild to those 
scored as moderate or high. Hence statistical analysis was performed by 
dichotomising the FN IHC score into high expression / positive (moderate and 
strong scores) and low expression / negative (negative and low scores). The 
result of the FN scoring was available in 190 MBC cases. In the MBC cohort, 
114 cases (60%) were FN positive and the rest were negative (n =76 and 40%). 
Fibronectin showed a strong positive association with nodal status (χ2 = 7.78; p 
= 0.02). Fibronectin didn’t show any statistically significant association with 
other known tumour specific prognostic indicators. There was a weak 
association between FN and AR (χ2 = 3.732; p = 0.054). However fibronectin 
didn’t show any statistically significant association with other known prognostic 
biomarkers (hormonal biomarkers, cytokeratins, Ki67 and HER2). 
The 5 year overall survival analysis was performed using Kaplan-Meier survival 
curve. There was a definite trend towards poor 5 year OS with positive FN 
expression (p = 0.06) (Figure 31). On Cox univariate regression analysis, FN 
showed only a trend towards predicting poor OS at 5 years (OR = 5.476 (CI = 
0.75 to 40.2); p = 0.09). In keeping with the results of the univariate analysis, 
FN was not found to be an independent predictor of OS on multivariate 
analysis. 
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Figure 31: Kaplan-Meier survival curve at 5 years for Fibronectin in Male Breast 
Cancer 
The survival curve shows a trend towards poor 5 year overall survival with positive 
Fibronectin expression. Patients were censored when they ceased to be followed up 
for any reason but had not died due to breast cancer.  
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4.5 DISCUSSION 
The heterogeneous nature of FBC is well established and has got prognostic 
significance (Hu et al., 2006, Sorlie et al., 2003, Perou et al., 2000). Compared 
to FBC, there is a paucity of studies in MBC to understand the molecular 
biology. Recently, Johansson et al (2012) has classified MBC into two distinct 
sub-groups luminal M1 and M2 (Johansson et al., 2012). They correlated well 
with the previously described male complex and simple sub-groups which were 
identified using aCGH (Johansson et al 2011). The luminal M1 and M2 sub-
groups were unique and different from that of the established FBC sub-types 
(Giordano et al., 2004). However there were also similarities noted between 
male and female breast cancer suggesting that the fundamental genes involved 
in the disease process might be similar (Johansson et al., 2011, Rudlowski et 
al., 2006, Tirkkonen et al., 1999). 
The bidirectional cross talk between the breast epithelial and stromal cells has 
been implicated in normal breast growth and differentiation as well as in the 
progression of malignancy (Schedin and Hovey, 2010). Stroma is the major 
component of the adult human breast (connective tissue 60% and fat 20%) with 
only 20% constituting for the epithelial elements (Howell et al., 2005, Wiseman 
and Werb, 2002). The stroma can be either inter-lobular or intra-lobular and 
supports both the vascular and lymphatic system as well provides scaffolding 
for the growth of the epithelial cells. The major component of the Inter-lobular 
stroma is collagen type 1, followed by collagen type 2 both making the inter-
lobular stroma denser (Polyak and Kalluri, 2010). Fibronectin was found to be 
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more abundant in the normal inter-lobular stroma compared to intra-lobular 
stroma using immunofluorescence method (Ferguson et al., 1992). 
There are pertinent differences in the development of male and female breast. 
The female breast ductal system undergoes rapid allometric growth and 
differentiation from puberty onwards under the stimulation of oestradiol resulting 
in the formation of the terminal ductal lobular units (TDLU) (Pelekanou and 
Leclercq, 2011). Conversely in the male breast there is minimal glandular 
formation with abrupt termination of the terminal ducts. Hence there is very little 
intra-lobular stroma compared to female breast. The inter-lobular stroma may 
be variable and may be comparable to female breast but less in volume. Hence 
it would be reasonable to hypothesise that there will be inherent differences in 
the development and progression of MBC compared to FBC.  
It has been shown in FBC that, substantial changes occur in the ECM during 
normal growth and development. However during progression of normal breast 
to malignancy, only minimal gene expressional changes occur in the inter-
lobular stroma compared to the epithelial compartment, where most of the 
changes seem to be taking place (Vargas et al., 2012). Most of the studies in 
this field were conducted using intra-lobular stroma and identified the changes 
were occurring mainly in the epithelial compartment (Knudsen et al., 2012, Ma 
et al., 2009). There is no published evidence within the literature on the 
changes which occur in the stromal compartment during progression from 
normal male breast to malignancy.  
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The results of the GEP of matched male and female breast cancer patients 
showed 656 differentially expressed genes (after exclusion of the sex-linked 
genes). Most of the genes (n = 487) were up-regulated. The results of Gene 
Ontology, individual functions of the top 10 up-regulated genes and hierarchical 
cluster group analysis showed the role of differentially expressed genes in 
ECM. The main themes emerging from the GO analysis were cell adhesion, 
cell-substrate adhesion, cell-matrix adhesion and collagen fibril organization 
(Chapter 4, Result section 4.4, Table 11, Page no. 125). The analysis 
undertaken by Johansson et al (2012) in MBC also showed similar GO 
biological process in the luminal M1 subgroup.  
Subsequent analysis and comparison with publically available data sets of 
normal vs. FBC stroma identified 64 common differentially expressed genes 
(Chapter 4, Result section 4.4, Table.14, Page no. 130). Similarly there were 
134 up-regulated and 39 down-regulated common genes, when this cohort was 
compared with normal vs. FBC GEP results available in the public repositories 
(Chapter 4, Result section 4.4, Table.15, Page no. 132). Together there were a 
total of 15 common differentially expressed genes identified from this analysis 
(all of them up-regulated in MBC) that was shown to have a role in the ECM 
during cancer progression. Most of these genes were involved in secreting 
proteins responsible for the production (COL12A1, COL1A1, COL1A2, 
COL3A1, COL6A3, COL10A1, COL11A1, COL8A1 and FBN1) or degradation 
(SPARC, MMP11, MMP13 and SERPINA) of ECM. Both FN1 and ITGB8 were 
unique in that the former facilitates cell-cell / cell-matrix adhesion and the latter 
is a transmembrane receptor that bridges cell-cell and cell-matrix interaction.  
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The FN1 gene encodes for fibronectin, which has unique functions in the ECM 
(Hynes and Yamada, 1982) and epithelial mesenchymal transition (EMT) (Park 
and Schwarzbauer, 2014, Foroni et al., 2012, Sung et al., 2011). Fibronectin is 
a large molecular weight glycoprotein (440kDa) present in the plasma (plasma 
fibronectin) and connective tissue (cellular fibronectin) (Hynes and Yamada, 
1982). There are structural and functional similarities and difference amongst 
cellular and plasma FN (Hynes and Yamada, 1982). The plasma fibronectin is a 
dimer compared to the cellular fibronectin, which can be either a dimer or a 
polymer. The main functional difference is the more active role played by the 
cellular fibronectin in transformed cells and in haem-agglutination (Hynes et al., 
1978, Yamada and Kennedy, 1979). 
 
Figure 32: Model of fibronectin monomer 
The three different repeating units are represented in different colours. The disulphide 
bond at the carboxyl terminal joins the monomers. The alternative splicing of the RNA 
at three repeats (represented in red box) results in EDA, EDB and III CS splice 
variants.  
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FN molecule is a heterodimer of similar but not identical polypeptides connected 
together by disulphide bonds (Kornblihtt et al., 1985) (Figure 32). The diversity 
of FN protein has been attributed to the alternating splicing occurring in at least 
3 regions, extra domain A (EDA), extra domain B (EDB) and type III homology 
connecting segment (IIICS) in the pre-mRNA (Gutman and Kornblihtt, 1987, 
Zardi et al., 1987, Schwarzbauer et al., 1987, Kornblihtt et al., 1984). The 
inclusion or exclusion of these regions is tissue and species specific 
(Schwarzbauer et al., 1987, Schwarzbauer et al., 1983). The alternative splicing 
in these 3 regions can result in the formation of various known splice variants of 
FN. 
The EDB sequence of the FN is almost undetectable in normal adult tissue and 
is expressed more during tissue remodeling, i.e. embryogenesis in foetal 
tissues, wound healing and during angiogenesis in tumours (Carnemolla et al., 
1989, Ffrench-Constant et al., 1989). There are two types of oncofoetal FN 
reported within the literature, the one generated by alternative splicing of EDB 
of the FN pre-mRNA and the other generated by O-glycosylation in the splicing 
region of type III CS (Carnemolla et al., 1989). The oncofoetal FN (i.e. EDB-FN 
and IIICS sequence FN) is not expressed in normal breast tissue and found to 
be expressed in the tumour vessels and stroma (Kaczmarek et al., 1994). The 
oncofoetal FN isoforms also seems to be differentially distributed in the 
neoplastic tissues i.e. the EDB-FN present more in the tumour associated 
vessels and the IIICS sequence FN in the extracellular matrix tumour stroma 
(Kaczmarek et al., 1994). 
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There are two mechanisms described within the literature explaining the 
synthesis of fibronectin. A positive feedback resulting from an increase in 
stiffness of the ECM by FN will lead to increase in production of the FN by the 
epithelial cells (Williams et al., 2008). There is also a paracrine mechanism of 
regulation of FN synthesis by breast stromal cells through hormonal (oestrogen 
and/or progesterone) regulation of mammary epithelial cells (Woodward et al., 
2001, Ferguson et al., 1992).  
There is evidence within the literature supporting the role of FN in promoting cell 
matrix adhesion and/or spreading in a variety of mediums including collagen, 
gelatine and fibrin (Grinnell et al., 1980, Grinnell, 1978). FN acts as a mediator 
for the adhesion of fibroblasts to collagen (Pearlstein, 1976). In cell culture 
studies, it was observed that adult human fibroblasts attaches to FN in the 
presence of either type 1 or 4 collagen (Terranova et al., 1986) and laminin can 
competitively block FN binding to type 4 collagen (Terranova et al., 1986). It has 
been proposed that such competition between laminin and FN may be 
contributory in preventing the fibroblasts from invading the epithelial side of the 
basement membrane (Yamada, 1991). This could also explain the lack of FN in 
the basement membrane of adult tissue as the normal tissue matures from 
embryonic state with the presence of FN in the basement membrane. 
Fibronectin can influence cell differentiation and morphogenesis (Yamada, 
1991). FN is essential for the developmental branching (morphogenesis) of 
salivary gland, lung and kidney through facilitating cleft formation by conversion 
of cell-cell adhesion to cell-matrix adhesion (Sakai et al., 2003).  Similarly FN 
was shown to be an essential effector for the breast acinar morphogenesis 
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(Williams et al., 2008). Fibronectin was down regulated during the normal acinar 
morphogenesis and over expression in MCF-10A cells results in increase in the 
acinar size with loss of the acinar lumen (Williams et al., 2008).  
The loss of cell surface FN has been implicated in the tumourigenic potential of 
various transformed and untransformed cell lines (Chen et al., 1979, Gallimore 
et al., 1977). Considering FN role in cell adhesion and the inherent invasive 
properties of cancer cell makes it a plausible argument for the loss of FN from 
cell surface during oncogenic transformation. The reason for the loss appears to 
vary from reduced production (Hynes et al., 1978, Olden and Yamada, 1977), 
reduced binding (Wagner et al., 1981, Olden and Yamada, 1977, Hayman et al., 
1981, Hynes et al., 1978, Vaheri and Ruoslahti, 1975) and increased 
degradation (Olden and Yamada, 1977). However it is yet to be consistently 
validated in animal or human cancer tissues.  
Both the cellular binding domain (CBD) and the N-terminal domain of FN play 
an important role in angiogenesis, with the former playing a more critical role 
(Kim et al., 2000). The angiogenic potential of FN depends on the presence of 
an intact CBD which can bind to α5β1 integrin and growth factor stimulation (Kim 
et al., 2000). The α5β1 integrin is very selective for fibronectin as it requires the 
specific peptide sequences on the ninth (PHSRN) and tenth (RGDS) type III 
repeats of fibronectin for ligand recognition (Aota et al., 1994, Hynes, 1992). 
The selective inhibition of α5β1 integrin can lead to inhibition of tumour growth 
and angiogenesis (Kim et al., 2000).  
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Fibronectin is thought to be up-regulated during the EMT process (especially 
type 2 and type 3 EMT) and considered as a marker for detection of EMT 
phenotype of cancer (Foroni et al., 2012, Sung et al., 2011, Yang et al., 2007, 
Strutz et al., 2002). There are two proposed mechanisms through which FN 
promotes changes during EMT. The first one is through activation of Stat3 
(Signal transducer and activator of transcription 3), which regulates cell 
proliferation, growth and survival (Idowu et al., 2012, Marotta et al., 2011). FN 
activates Stat3 in an Epidermal Growth Factor Receptor (EGFR) independent 
manner through FAK/Pyk2:Jak2 pathway in breast cancer cell lines (MDA-
MB21) (Balanis et al., 2013). In MCF-10A cell lines, FN was shown to activate 
Smad2 independently as well as through TGFβ1 (Transforming Growth Factor 
β1) to promote epithelial changes during EMT. It is entirely possible that, the up-
regulation of FN observed during EMT could be both a cause and result of 
tumour progression.   
In the normal breast tissue there is conflicting reports within the literature about 
the expression of FN. Fibronectin is detected in small quantities or absent in the 
normal mammary tissue (Ioachim et al., 2002, Helleman et al., 2008, Kadar et 
al., 2002, Koukoulis et al., 1993, Christensen, 1992). The studies in which FN 
expression was seen in normal mammary tissue it was confined mainly to the 
stroma and also in the basement membrane region of the epithelial cells 
(Friedman et al., 1984, Stampfer et al., 1981). Gould et al (1990) showed that, 
FN expression was faint or mostly absent in the intra-lobular stroma and seen 
mainly in the inter-lobular stroma (Gould et al., 1990) . Amongst the various 
splice variants of FN, only the EDA of FN was found in adult breast ducts and 
acini (Koukoulis et al., 1993).  
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However more extensive expression of FN was observed in breast cancer. The 
distribution of FN was mainly around the peri-tumoural stroma (Gould et al., 
1990, Friedman et al., 1984, Stampfer et al., 1981) and intra-tumoural stroma 
(Gould et al., 1990). The breast cancer epithelial cells were mostly negative 
(Gould et al., 1990, Friedman et al., 1984), however some have reported 
minimal staining within the cytoplasmic region of the epithelial cells 
(Christensen et al., 1985, Stampfer et al., 1981). All three known splice variants 
of FN are expressed in breast cancer, with expression of EDB FN and 
oncofoetal FN restricted to breast cancer and foetal breast tissue (Koukoulis et 
al., 1993). The FN expression was stronger and more extensive in invasive 
ductal cancer compared to invasive lobular cancer (Gould et al., 1990). In 
summary, the expression of FN is minimal in normal breast tissue, but 
enhances through the spectrum of fibrocystic and hyperplastic breast tissue 
with most extensive staining noted in the stromal elements of breast cancer 
(Ioachim et al., 2002, Gould et al., 1990).  
Even though there is emerging evidence regarding epithelial FN in FBC, only 
the stromal expression was evaluated in the MBC using IHC. This was due to 
the following reasons, a) IHC was performed to evaluate the stromal expression 
FN and relate it to the GEP data mining results identified in matched male and 
female breast cancer samples b) there is ambiguity about the role of epithelial 
FN in breast cancer c) the FN expression was patchy within the tumour 
epithelial cells and was absent in most of the cases reviewed in this cohort.  
The FN immunoreactivity was specific to stroma and around 60% of the cases 
were positive for fibronectin. FN did not show any association with proliferative 
148 
 
markers (like Ki67 and Survivin) or tumour grade in this cohort. Similarly other 
than a weak association with AR, there was no significant association with 
known prognostic biomarkers (ER, CK5/6, CK18 and HER2).   
There was a strong positive association between FN and nodal status. 
Helleman et al (2008) also found a similar strong association between nodal 
status and FN gene expression in FBC patients. Similarly in paired breast 
tumour and lymph node metastatic samples, the FN protein expression was 
elevated in the ECM of the lymph node metastatic samples (Hao et al., 2004). 
However, the FN gene was under expressed in the lymph node metastasis 
(Hao et al., 2004). Hence, Hao et al (2004) proposed that “there might be a 
negative feedback of FN gene expression by the secreted protein or the FN 
protein being secreted by other cells into the ECM”. Ioachim et al (2002) 
showed that there was cytoplasmic staining of FN in only 10% of the primary 
tumour cells compared to 50% in the involved lymph node metastasis. 
Extrapolation of the findings by Hao et al (2004) and Ioachim et al (2002) would 
suggest a paracrine mechanism leading to increased expression of FN in 
metastatic lymph nodes.   
The prognostic role of FN thus far has been evaluated only in FBC. Generally in 
FBC, FN expression (gene or protein) has been associated with a worse clinical 
outcome (Ioachim et al., 2002, Helleman et al., 2008, Bae et al., 2013, Yao et 
al., 2007). In this MBC cohort there was a definitive trend towards poor 5 year 
OS amongst FN positive patients. However on multivariate analysis, FN 
expression was not found to be an independent predictor of survival in the MBC 
cohort. Similarly even in FBC, stromal expression of FN was not proven to be 
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an independent predictor of survival. Conversely epithelial FN expression was 
found to be an independent predictor of worse survival in FBC patients (Bae et 
al., 2013). The other published studies on the prognostic role of FN protein 
expression were biased as in one a less reliable IHC technique 
(immunoperoxidase method) was used (Christensen et al., 1988) and in the 
other plasma FN was analysed instead of cellular FN (Takei et al., 1995). 
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4.6 CONCLUSION 
The gene expression profiling in matched male and female breast cancer 
samples showed up-regulation of genes involved in ECM synthesis (COL12A1, 
COL1A1, COL1A2, COL3A1, COL6A3, COL10A1, COL11A1, COL8A1 and 
FBN1) and degradation (SPARC, MMP11, MMP13 and SERPINA), a trans-
membrane receptor (ITGB8) and a gene involved in ECM re-modelling (FN1). 
The result was validated by evaluating fibronectin expression in MBC tissue 
microarrays. There was high stromal expression of fibronectin in 60% of the 
MBC cases. High fibronectin expression was also found to have a strong 
association with nodal status and a trend towards poor survival in the MBC 
cohort.  
Changes occurring in the ECM during tumour progression is complex with 
interaction between various ECM molecules and their receptors, as well as 
ECM based recruitment and organisation of other molecules. Hence the role or 
changes induced by a single gene or protein may not be substantial.  However, 
single gene studies are essential in bridging the gap in knowledge to better 
understand the larger role played by ECM during tumour progression. 
Examining the wider role of ECM genes identified in this study is on-going within 
the research group.  
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4.7 LIMITATIONS AND FUTURE DIRECTION  
A few limitations of GEP of matched male and female breast cancer samples 
and validation of the results in MBC TMA’s should be considered while 
interpreting and extrapolating the results of this research.  
The mRNA was extracted from sections made from FFPE tumour rich MBC 
samples. In this study, neither macro nor micro-dissection was performed to 
extract tissues separately for GEP from cancer epithelial cells and intra or inter-
lobular stroma. This would have been ideal to establish true changes taking 
place in each compartment of the MBC. However H&E staining of the section 
was evaluated by a breast pathologist (AMH) to ensure that each FFPE section 
used for mRNA extraction contained sufficient amount of cancer and stromal 
elements.  
The GEP was performed with an aim to identify differentially expressed genes 
in matched male and female breast cancer patients. Hence differentially 
expressed genes identified might not represent the molecular changes 
occurring in male breast during progression from normal to malignancy. An 
attempt was made to extrapolate this finding by comparing with publically 
available FBC data sets to identify common differentially expressed genes 
during cancer development and progression. Hence the results derived from 
data mining needs further independent validation to improve its external validity.  
The use of tissue microarray for studying stromal expression of FN may not be 
ideal. A tissue microarray would be inadequate to study the advancing edge of 
a tumour, where FN expression is proposed to be highest due to its role in ECM 
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remodelling (Ioachim et al., 2002). Similarly it would be difficult to quantify and 
evaluate the expression of FN in inter and intra-lobular stroma in a TMA to 
confirm or refute the findings drawn from studies conducted in FBC (Gould et 
al., 1990). However there are many advantages for using TMAs in MBC, 
including evaluation of large number of samples in a systematic way by using 
standardised IHC methods (Ilyas et al., 2013). 
There is a vast amount of data generated through the GEP analysis. The 
differentially expressed genes with a role in ECM remodelling (Table 16; 
Chapter 4, Section 4.4, Page no. 133) would be an ideal start point for further 
translational research. The protein end products of the genes identified can be 
evaluated for prognostic or predictive role in MBC cohort using 
immunohistochemistry. The GO and IPA results provide another platform for 
further research. The GO analysis has shown (Table 11; Chapter 4, Result 
section 4.4, Page no. 125) enrichment of cellular adhesion and collagen fibril 
organization amongst the top 10 enriched biological process. The role of these 
biological process and pathways in the development and progression of MBC 
could be evaluated in future studies. The top 10 up and down regulated protein 
encoding non-sex linked genes identified during the data mining provides 
another platform for pursuing further research (Table 12 and 13, Chapter 4, 
Section 4.4, Page no. 129). Each of these genes and their end products could 
unveil details that could explain the natural progression of MBC.  
A future aim should be to perform GEP in matched male normal and breast 
cancer tissue samples. However this will be challenging due to the difficulties in 
obtaining normal male breast tissue for research purpose. A compromise may 
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be to use breast tissue with gynaecomastia changes, although it might also not 
be truly representative of normal breast milieu. However gynaecomastoid tissue 
has been used as a surrogate for normal male breast tissue for evaluating the 
microRNA expression (Lehmann et al., 2010, Fassan et al., 2009). Careful 
consideration should also be given regarding the proliferative changes occurring 
in the glandular and/or connective tissue of the gynaecomastoid breast while 
interpreting GEP results if used as surrogate for normal male breast tissue. 
Another option would be to collect blood samples from healthy male volunteers 
as controls (germline DNA) and compare it with tumour DNA to identify the 
differential expression of genes.  
Future studies should also aim to micro-dissect the tumour to better understand 
the role played by tumour microenvironment in the development and 
progression of MBC. This will enable us to understand the changes that is 
taking place in the epithelial and stromal compartments of MBC compared to 
normal or gynaecomastoid breast tissue. This will also facilitate direct 
comparison with FBC gene expression profiles available through the public 
repositories. 
The external validity of the study was compromised due to the missing data and 
lack of information about disease free survival (DFS). The lack of adequate 
power could have led to type II error. This may have been one of the 
contributing factors for the inability to detect independent predictability amongst 
various biomarkers tested in the MBC cohort. In 2012, there were only 353 
cases of MBC diagnosed in the UK, which accounts for less than 1% of all the 
cancers diagnosed in men (CRUK, 2012). When dealing with a disease of such 
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low incidence, it is often difficult to achieve sufficient statistical power to provide 
answers to all relevant research questions. Despite best effort by the team, 
there was significant amount of missing clinical, pathological and survival data 
(40%) in this cohort. However even after exclusion of cases without adequate 
clinical, pathological and follow-up data, there was reasonable sample size (n = 
238) available for statistical analysis. The sample size of the current study 
remains to be the one of the largest amongst those published within the 
literature.  
The survival analysis was performed using OS in this cohort with a median age 
of 68 years (IQR = 17 years). Hence the results of survival analysis might have 
been affected by analytical bias. The information about DFS could have been 
ideal; however it was difficult to obtain as the samples were collected through 
collaboration from multiple international centres over many years with some of 
the data originating as far as back in the early 90’s. There was also lack of 
adequate and consistent adjuvant treatment data from most of the centres. 
Hence it has not been possible to account for the influence of various adjuvant 
treatments during the statistical analysis. Even though no major breakthroughs 
or innovative therapeutic advances have emerged in adjuvant therapy of MBC 
over recent years, accounting for this confounding factor could have improved 
the internal and external validity of this study.  
In spite of the limitations discussed, this study is one of the largest cohort of 
MBC evaluated for the expression and prognostic role of various biomarkers. 
The results have shown promising insight into MBC biology at molecular and 
protein levels. It is essential to further pursue both the biomarker and gene 
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expression findings deduced from this study to better understand MBC biology. 
The limitations and areas for improvement identified from this study should lay 
foundations for conducting future studies in this field. The rarity of MBC 
necessitates the need for seeking an international collaboration or consortium 
(Korde et al., 2010) to collect MBC samples in a systematic way to facilitate 
future research.  
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6 APPENDICES 
6.1.1 Appendix 1: Ethics approval  
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6.1.2 Appendix 2: Breakdown of patients selected for statistical 
analysis  
Table 18: Selection of patients from MBC TMA cores for final statistical analysis  
Characteristics Frequency Details 
Total Number of patients in whom TMA cores 
were available 428   
Missing core  19 
MBC 067, 087, 089, 091, 
216,217, 227, 228, 231, 236, 
240, 241, 252, 260, 261, 
301, 317, 429, 486 
      
Total number of patients available for analysis  409   
      
Clinical and/or Pathological data missing  28   
Survival data missing  37   
Both survival and Clinical and/or Pathological data 
missing  143   
      
Total number analysed for 
descriptive/association analysis 238 409 - 171 (143+28) = 238 
      
Total number analysed for survival analysis  229 409 - 180 (143+37) = 229 
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6.1.3 Appendix 3: RNA quality control standards 
Table 19: ALMAC diagnostic expression quality control acceptance criteria 
Sample type Almac diagnostic QC criteria 
Spectrophotometer 
A260-280 
Bio-analyser 
Total RNA* 1.68 – 2.08 (1.38 -2.18)** Two distinct peaks (18S and 28S) 
NuGEN FFPE processing  
cDNA > 1.70 NA 
Fragmented DNA NA ≥ 80% of product should be 200 
bases or less 
*Not applicable to RNA extracted from FFPE material. **Tolerance limits: Almac diagnostics processed 
samples within the tolerance limits if accompanied with a satisfactory bio-analyser profile.  
Table 20: RNA quality control
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6.1.4 Appendix 4: cDNA quality controls 
Table 21: cDNA quality control  
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6.1.5 Appendix 5: GeneChip quality control (QC) and data 
integrity assessment 
The variability in the quality of GeneChip profile QC results is typical when the 
material is derived from FFPE. Hence in order to improve the analysis, data 
transformation was performed after removing the array quality variable. 
Principal component analysis (PCA) (Figure 33a and 33b) and hierarchical 
clustering (Figure 34) was performed for data integrity analysis. In our cohort, 2 
samples failed the analysis for background intensity assessed using mean 
absolute deviation (mad) (Table 22). However, both these samples were 
included in the final analysis as they passed all other GeneChip QC measures 
(Table 23 and 24) and data integrity analysis (Figure 33 and 34). Conversely, 3 
MBC samples failed the percentage of present call (less than 15%), scaling 
factor and data integrity tests (Table 23 and 24). Hence these samples were 
excluded from the final analysis. 
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Figure 33: PCA plot showing sample groups coloured by gender and by 
percentage present calls  
Data integrity analysis was performed using principal component analysis (PCA). (a) 
PCA based on gender groups - Red circle = Male, Blue circle = Female. (b) PCA based 
on percentage present calls -The intensity of the colour depends on the gene 
expression, Red = Over-expressed and Green = Under-expressed. 
 
MALE 
FEMALE
PCA mapping  (34.2%)
PCA mapping  (34.2%)
Figure. 33a
Figure. 33b
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Figure 34: Hierarchical clustering showing the relationship between the samples  
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Table 22: Average background intensity value for each chip used in the 
experiment  
Sample Name  Background  Sample Passed?  
S0712F0001a  26.46  Yes  
S0712F0002a  24.51  Yes  
S0712F0003a  26.12  Yes  
S0712F0004a  24.95  Yes  
S0712F0005a  23.15  Yes  
S0712F0006a  23.77  Yes  
S0712F0007a  23.68  Yes  
S0712F0008_vac  24.29  Yes  
S0712F0009a  26.71  Yes  
S0712F0010a  26.13  Yes  
S0712F0011_vac  24.52  Yes  
S0712F0012a  29.64  No  
S0712F0013a  24.82  Yes  
S0712F0014a  24.56  Yes  
S0712F0015a  24.63  Yes  
S0712F0016a  26.08  Yes  
S0712F0017a  24.78  Yes  
S0712F0018a  25.30  Yes  
S0712F0019a  24.59  Yes  
S0712F0020a  23.63  Yes  
S0712F0021a  23.92  Yes  
S0712F0022a  22.70  Yes  
S0712F0023a  23.23  Yes  
S0712F0024a  23.17  Yes  
S0712F0025a  30.91  No  
Median  24.59  
Std(mad)=1.4826*mad 1.349166  
 
Table 23: Percentage of present call for the arrays 
Sample Name  % Present Call  Sample Passed?  
S0712F0001a  27.80  Yes  
S0712F0002a  11.90  No  
S0712F0003a  8.30  No  
S0712F0004a  26.80  Yes  
S0712F0005a  19.50  Yes  
S0712F0006a  31.50  Yes  
S0712F0007a  20.10  Yes  
S0712F0008_vac  16.80  Yes  
S0712F0009a  28.90  Yes  
S0712F0010a  29.00  Yes  
S0712F0011_vac  9.40  No  
S0712F0012a  34.60  Yes  
S0712F0013a  23.80  Yes  
S0712F0014a  17.20  Yes  
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S0712F0015a  25.90  Yes  
S0712F0016a  16.60  Yes  
S0712F0017a  26.50  Yes  
S0712F0018a  26.70  Yes  
S0712F0019a  25.60  Yes  
S0712F0020a  19.50  Yes  
S0712F0021a  29.60  Yes  
S0712F0022a  26.90  Yes  
S0712F0023a  23.60  Yes  
S0712F0024a  23.10  Yes  
S0712F0025a  23.00  Yes  
Median  23.80  
Std(mad)=1.4826*mad  6.37518  
Max  34.60  
Min  8.30  
Range  26.30  
 
Table 24: Scaling factor for the arrays 
Sample Name  Scaling Factor Sample Passed?  
S0712F0001a  13.348  Yes  
S0712F0002a  42.061  No  
S0712F0003a  71.461  No  
S0712F0004a  24.520  Yes  
S0712F0005a  33.118  Yes  
S0712F0006a  14.788  Yes  
S0712F0007a  31.476  Yes  
S0712F0008_vac  39.227  Yes  
S0712F0009a  20.923  Yes  
S0712F0010a  20.537  Yes  
S0712F0011_vac  51.182  No  
S0712F0012a  14.627  Yes  
S0712F0013a  20.730  Yes  
S0712F0014a  30.940  Yes  
S0712F0015a  28.412  Yes  
S0712F0016a  33.992  Yes  
S0712F0017a  23.976  Yes  
S0712F0018a  19.633  Yes  
S0712F0019a  24.277  Yes  
S0712F0020a  37.876  Yes  
S0712F0021a  18.801  Yes  
S0712F0022a  22.301  Yes  
S0712F0023a  26.298  Yes  
S0712F0024a  28.803  Yes  
S0712F0025a  21.579  Yes  
Median  24.520  
Std(mad)=1.4826*mad 8.4789894  
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6.1.6 Appendix 6: Bioinformatics  
The general filtering was carried out using background expression and variance 
filters to identify a list of 14, 949 probe sets. The criteria used was to remove 
any probe set with an expression on the background level (p = 0.3). Similarly, 
any probe set with a variance below the mean global variance was removed in 
an intensity dependent manner (α-value = 0.9). The data was then subjected to 
advanced fold change filtering based on the intensity and variation of probe sets 
between the groups. Student’s t-test was performed to determine differentially 
expressed probe sets statistically and false discovery rate (pFDR) was 
calculated to account for multiple test correction. Hierarchical agglomerative 
clustering was undertaken amongst differentially expressed genes, using both 
less stringent (Significance level for log fold change = 0.05) and stringent 
criteria (Significance level for log fold change = 0.01). The agglomerative 
method starts with each sample/gene as a separate cluster and merges them 
into successive larger clusters. The analysis was performed in Partek GS v6.5. 
Functional enrichment analysis of differentially expressed genes identified with 
the less stringent criteria (n=735) was undertaken using Ingenuity Pathway 
Analysis (IPA v9.0 build 116623, Ingenuity® Systems, content version 3211) 
and Gene Ontology (GO) analysis using Functional Enrichment Tool (FET 
version 1.0). The significance of the association between differentially 
expressed genes to the total number of genes in a canonical pathway/GO term 
was expressed as a ratio and Fisher’s exact test was performed to establish 
statistical significance. Benjamini & Hochberg adjusted p-value was also 
calculated to account for multiple testing and represented as pFDR.  
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